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ABSTRACT 
The molecular pathology of triple negative breast cancer (TNBC) is poorly understood, 
consequently, no successful forms of therapy have been developed. Thus an improvement 
of knowledge and subsequently the discovery of novel treatments for the disease are 
imperative. It has been found that deregulation of the Notch signalling pathway promotes 
tumourigenesis in breast tissue. Therefore, it was of interest here to investigate whether the 
Notch signalling pathway is deregulated in TNBC and whether its abrogation affects the 
proliferation and migration of TNBC cell lines. The normal growth characteristics of 
MCF-7 cells (hormone sensitive) were compared to those of MDA-MB-231 and MDA-
MB-436 (both hormone insensitive) cell lines and were determined by real-time cell 
impedance assays, using the ―xCELLigence‖ instrument. Thereafter, cells were treated 
with gamma secretase inhibitors (GSI) of the Notch signalling pathway. The MCF-7 cell 
line proliferated faster than the MDA-MB-231 and MDA-MB-436 cell lines. The 
proliferation of the MDA-MB-231 and MDA-MB-436 cell lines decreased significantly 
following treatment with inhibitors. Confocal microscopy was used to assess levels of the 
Notch intracellular component (a gamma secretase cleavage product) and E-cadherin (a 
breast tumour suppressor marker), pre- and post- treatment. Prior to drug treatments, 
confocal microscopy showed that the Notch intracellular component was highly expressed 
in the MDA-MB-231 cell line, and it was low in the MDA-MB-436 cell line, compared to 
the MCF-7 cell line. Following drug treatments, confocal microscopy showed a decreased 
expression of the Notch intracellular component in all three cell lines. Prior to drug 
treatment only the MCF-7 cell line expressed E-cadherin which was reduced post 
treatment. Subsequently the cell migration assays revealed that migration is reduced post-
vi 
 
drug treatment in all three cell lines, despite no statistical significance. Overall the MDA-
MB-231 and MDA-MB-436 cell lines were more significantly sensitive to the gamma 
secretase inhibitors compared to the MCF-7 cell lines. Therefore these observations 
suggest that the Notch signalling pathway is a plausible novel therapeutic target in the 
treatment of TNBC. 
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CHAPTER 1: INTRODUCTION  
1.1 Review of literature 
1.1.1 Breast cancer statistics and classification 
Breast cancer (BC) is the most common cause of cancer related deaths among women 
worldwide and it is now estimated that it represents one in four cancers afflicting women 
Ferlay et al. (2015). The most recent GLOBOCAN study reveals that BC incidences have 
risen by approximately 20% between 2008 and 2012 (Ferlay et al., 2015).  In South Africa 
(SA), it is estimated that one in thirty five women will be diagnosed with the disease 
making it the leading cause of cancer related deaths in South African women (CANSA, 
2014).   
BC is a heterogeneous complex of diseases that have been classified into five subtypes 
namely: Luminal A; Luminal B; Human epidermal growth factor-2 receptor (HER-2) 
positive (HER-2
+
); Normal breast-like and Basal-like BC (BLBC) (see Table 1.1) (Sotiriou 
and Pusztai, 2009, Perou et al., 2000, Sorlie et al., 2003). The classification was based on 
gene expression patterns, wherein each subtype displayed distinct biological features 
(Yersal and Barutca, 2014, Rakha and Ellis, 2011), which give rise to the differences in the 
2 
 
response patterns to various treatment modalities and to clinical outcomes (Yersal and 
Barutca, 2014, Liu et al., 2014). 
 
The Luminal subtype arises from the luminal epithelium of the breast ducts and is sub-
classified into Luminal A and Luminal B breast tumours (Vuong et al., 2014). While both 
express oestrogen receptors (ER) and progesterone receptors (PR), the Luminal A tumours 
have higher levels of ER, compared to the Luminal B tumours (Sorlie et al., 2001, Zhang 
et al., 2014). Furthermore, the Luminal A tumours have a lower proliferation index and are 
highly sensitive to current endocrine therapeutics and to aromatase inhibitors (Ignatiadis 
and Sotiriou, 2013). The Luminal B tumours express HER-2, thus these tumours have a 
higher proliferative index than Luminal A tumours (Zhang et al., 2014). This feature 
enhances their sensitivity to current anti-HER-2 therapies (Network, 2012, Ignatiadis and 
Sotiriou, 2013).   
Those tumours classified as normal breast-like, express genes characteristic of adipose 
tissues, and are negative for the basal myoepithelial markers, cytokeratin (CK) 5 and 
epithelial growth factor receptor (EGFR) (Yersal and Barutca, 2014, Vuong et al., 2014). 
This subtype however, remains controversial, as some researchers believe that it very 
likely represents normal breast cell samples that have been contaminated during technical 
work (Weigelt et al., 2010).  
The last subtype is the BLBC subtype. These tumours which originate from the basal 
myoepithelium are the most aggressive of all the tumour subtypes. They express high 
levels of basal myoepithelial markers, such as, CK5, CK14, CK17 and laminin; and they 
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lack the expression of ER, PR and HER-2 receptor, a feature described as ―triple 
negativity‖. Currently, there is no specific therapy for BLBC tumours.  
Table 1.1: Molecular classification of the five major breast cancers subtypes (Sorlie et al., 
2003). 
Subtypes Molecular classification Prevalence  
Luminal A ER
+
/PR
+
/HER-2
-
 50-60% 
Luminal B ER
+
/PR
+
/HER-2
+
 15-20% 
HER-2
 
Positive ER
-
/PR
-
/HER-2
+
 15-20% 
Basal-like ER
-
/PR
-
/HER-2
-
 8-37% 
Normal like ER-/PR-HER-2- / CK5- 5- 10% 
 
1.1.2 What is Triple negative breast cancer? 
1.1.2.1 The difference between the Basal-like breast cancer and Triple negative breast 
cancer 
BLBCs are the most aggressive BC subtype of the five discussed. They are diagnosed 
more frequently in young women of African ancestry (Badve et al., 2011). As mentioned 
above, a characteristic feature of BLBC is the lack of ER, PR, and HER-2 expression. In 
the research setting, this disease is defined via gene expression array analysis (Perou et al., 
2000). Since this approach is economically unfeasible in the clinical setting, 
immunohistochemical (IHC) analyses of hormone and growth receptors are used as 
markers for BLBC. As a consequence of this approach, BLBC became more commonly 
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known as triple negative breast cancer (TNBC) (Prat et al., 2013). However, research has 
demonstrated that as there is approximately 25% discordance between BLBC and TNBC, 
as not all BLBC are TNBC and vice versa (Yersal and Barutca, 2014, Prat et al., 2013).  
Microarray based studies on 12 publicly available TNBC data sets, which were composed 
of TNBC human tumours and TNBC cell lines revealed that only 70-80% of the tumours 
possessed the basal like phenotype and 20-30% were either luminal or had basoluminal 
phenotypes (Prat et al., 2013).Other microarray studies demonstrated that between 50-75% 
of TNBC tumours were of the basal like phenotype (Rakha et al., 2009, Perou, 2011, 
Nielsen et al., 2004). Moreover, up to 45% of BLBCs expressed the ER, PR and HER-2 
and 40-80% of TNBC expressed basal markers (Carey et al., 2010). It is also noted that a 
characteristic feature of the controversial normal breast-like tumours, lack ER, PR and 
HER-2 expression, which implies that they may also be considered ―triple negative‖. 
Evidently, research has shown that TNBC is not a reliable surrogate for BLBC and 
therefore, the terms should not to be used synonymously (Prat et al., 2013, Rakha et al., 
2009).  
Therefore, TNBCs are defined as breast tumours that lack ER, PR and HER-2 expression, 
and may fall into any of the other BC subtypes (Perou, 2011, Eiermann et al., 2012, Prat 
and Perou, 2011) .    
1.1.2.2 Molecular classification of Triple negative breast cancer 
The heterogeneity of this group has lead researchers to the inclination that TNBC may be 
comprised of a variety of molecularly distinct subgroups (Prat and Perou, 2011). In this 
regard the most prominent publication is by Lehmann and colleagues who analysed 
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ribonucleic acid (RNA) expression from 14 BC gene expression datasets that used breast 
tumours from women in the United States of America (USA), Europe and China as a 
training set, to develop gene signatures for TNBC subgroups (Lehmann et al., 2011). 
Through their analyses 2,188 genes from 386 TNBC tumours were identified (Lehmann et 
al., 2011). Consensus and k-means clustering of the tumour profiles revealed that there 
were six TNBC sub-groups which consisted of Basal-like 1 (BL1), Basal-like 2 (BL2), 
Mesenchymal like (ML), Mesenchymal stem like (MSL), and Luminal Androgen Receptor 
(LAR) (summarised Figure 1.1) (Lehmann et al., 2011) .   
Other researchers have employed different approaches to investigate or validate the 
―TNBC sub-group‖ hypothesis (Prat et al., 2013). Elsawaf and colleagues demonstrated 
that there are four distinct TNBC subgroups (Elsawaf et al., 2013). By using IHC 
combined with hierarchical clustering, they analysed 147 patient derived TNBC tumours, 
to assess the expression of basal and luminal cytokeratins. The subgroups were classified 
as Basal A, Basal B, Basoluminal and Luminal, with respect to the predominant pattern of 
cytokeratin expression (Figure 1.1) (Elsawaf et al., 2013). 
Each of these studies employed a different approach to test the hypothesis, each having 
advantages and disadvantages. The Lehmann study was larger and distinguished their 
subgroups based on the identification and clustering of 2,188 genes. In contrast, the 
Elsawaf study was smaller and evaluated the biomarker expression patterns on the 
tumours. The former study is more statistically and biologically powerful versus the latter. 
However, the Elsawaf approach is more economically and practically feasible for routine 
clinical diagnostics, more especially in an African setting.  
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 Furthermore, Prat and colleagues (Prat et al., 2010) identified another sub-group 
characterised by lower claudin expression levels through micro-ribonucleic acid (miRNA) 
expression analyses. Claudins represent a group of cell adhesion molecules that are 
associated with the formation and stabilisation of tight junctions (Escudero-Esparza et al., 
2011). These tumours were observed to be most aggressive compared to other subgroups 
(Prat et al., 2010). The clinical relevance of this subgroup as well as the aforementioned 
groupings is still under investigation, since subject of TNBC sub-classification is 
controversial. 
 Therefore, further research is warranted in order to reach a general consensus as to which 
approach is best suited to determine the molecular subgroup of a tumour. It is imperative 
that both the researcher and clinician agree to avoid tumour misclassifications, when 
diagnosing patients or when beginning a clinical trial or laboratory research.   
Despite the controversy, the research discussed provides valuable information concerning 
the complicated nature of TNBC and it is this complexity in addition to the lack of 
hormone and growth receptor expression as to why TNBC remains a challenge to treat and 
manage.  
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Figure 1.1 Summary of the two different methodological approaches applied to sub-classify 
TNBC. Immunohistochemical analyses of 147 TNBC tumours (red) based on hierarchical 
clustering of predominant patterns of basal and luminal cytokeratins revealed four distinct 
subgroups Basal A; Basal B; Basoluminal and Luminal TNBCs. Gene expression analyses of 337 
TNBC tumours (blue) were analysed by k-means and consensus clustering of 2,188 genes.  The six 
distinct sub-groups identified in this study were Basal-like 1 (BL1); Basal-like 2 (BL2), 
Mesenchymal-stem-like (MSL); Mesenchymal (M) and Luminal Androgen Receptor (LAR) 
(Elsawaf et al., 2013, Lehmann et al., 2011) .To-date the sub-classification of TNBC tumours is a 
topic of debate.[Diagram was created on Microsoft PowerPoint, 2010; Msibi, 2015] 
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1.1.2.3 Epidemiology and risk factors for Triple negative breast cancer 
1.1.2.3.1 Racial disparities 
It has been reported that TNBC is more prevalent in young black women compared to 
women of other races (Swede et al., 2011, Galukande et al., 2014). Stead and colleagues 
published data, collected from 415 female patients with invasive BC between 1998 and 
2006(Stead et al., 2009). This study consisted of an ethnically diverse population. It was 
observed that TNBC constitutes 20% of all tumours and 64% of these were tumours 
obtained from pre-menopausal black patients (age less than 50 years). The Clinical Breast 
Care Project (CBCP) studied the racial disparities between African American women 
(AAW) and Caucasian women (CW) with BC (Sturtz et al., 2014). It was found that 
TNBC diagnosis was significantly higher in AAW (28%) compared to CW (12%) (Sturtz 
et al., 2014). Most epidemiological studies on the disease have been conducted in the 
Western and European countries.  
 
Hitherto only two BC subtype studies have been published in SA. McCormack and 
colleagues examined the BC characteristics of 1,092 patients who attended Chris-Hani 
Baragwanath Hospital (CHBH), between 2006 and 2012(McCormack et al., 2013). From a 
racially diverse population they observed that TNBC was most prevalent in black women. 
The data is comparable to that obtained from USA based studies. Although informative, 
this study was limited to patients attending CHBH. A larger study with 10,047 BC patients 
from SA and Namibia was conducted between 2011 and 2013(Dickens et al., 2014a). The 
data concurred with others, that is, TNBC is more prevalent in black women and 
statistically it represents 17.4% - 21.9% of all BCs (Dickens et al., 2014a).  
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In other sub-Saharan countries epidemiological studies are few and small (Sayed et al., 
2014, Eng et al., 2014).  This emphasises the need for extensive epidemiological data 
collection in SA, as well as the rest of the sub-continent. 
1.1.2.3.2 Genetic risk factors 
Genomic instability and mutation is an enabling hallmark of tumorigenesis (Hanahan and 
Weinberg, 2011). Mutations in the genes enhance the susceptibility of cancer. Certain gene 
mutations are associated with particular cancers. The breast cancer susceptibility (BRCA) 
gene is a well-known BC gene. It’s been reported that women with a BRCA1 mutation 
have a more than 50% chance of development of TNBC (Zhang et al., 2012, Haiman et al., 
2011). In the Hellenic Cooperative Oncology Group study (HCOG), it was found that, that 
there were 65 deleterious BRCA1 mutations among the 403 TNBC patients that 
participated (Fostira et al., 2012). Additionally when the age at onset of the disease was 
considered, BRCA1 carriers increased dramatically with some 27% of women with TNBC 
diagnosed at or before the age of 50, whilst 36% diagnosed at or before the age of 40 had a 
BRCA1 mutation (Fostira et al., 2012). A report on similar observations was provided in a 
cohort of 469 TNBC patients (70% Caucasian and 19% AAW), 31% of the group had a 
BRCA1 and BRCA2 mutation (Greenup et al., 2013). When age at diagnosis was taken 
into account, the likeli-hood of carrying a BRCA1 or BRCA2 mutation increased (Greenup 
et al., 2013).  
 
Couch et al. assessed the frequency of mutation in 17 BC predisposition genes among 
1.824 TNBC patients when unselected for family history (Couch et al., 2015). Across the 
cohort, 14.6% of women had at least 1 deleterious gene mutation, predominantly BRCA1, 
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identified in 8.5% and BRCA2 identified in 2.7 % (Couch et al., 2015). Sporadic TNBC 
cases with BRCA1/2 mutations were strongly associated with younger age (Couch et al., 
2015). Furthermore the study discovered that the 15 other mutations were present at 
varying degrees in 3.7% of the women (Couch et al., 2015). The most frequent after 
BRCA1/2, were mutations in the Partner and Localizer of BRCA2 (PALB2) gene found in 
21 patients (1.2%) (Couch et al., 2015). The Couch study concurs with the HCOG study as 
38 % of mutations were found in women younger than 40 and the presence of mutation 
was associated with diagnosis at a significantly young age. 
 
In view of the high prevalence of TNBC in women of African ancestry than of European 
ancestry, genetics researchers have undertaken the task to discover gene susceptibility loci 
for this subtype of BC. A Meta-analysis of genome-wide association studies (GWAS) of 
ER negative BC in a mixed population of African and European ancestry identified a novel 
TERT-rs10069690 SNP in chromosome 5P15 for TNBC risk; however, allele frequency of 
rs10069690 was greater in women of African than of European ancestry (Haiman et al., 
2011). The data was confirmed in the Black Women’s Health Study (BWHS) in which 
only AAWs were examined (1199 cases and 1948 controls) (Palmer et al., 2013). While 
the functional significance of the findings are unknown, the results  do however support a 
genetic cause of TNBC that might partly contribute to racial or ethnic origin differences in 
the incidence of the disease (Palmer et al., 2013). 
1.1.2.3.3 Reproductive risk factors 
Reproductive factors are among the earliest and most well established BC risk factors. 
However, there are a few studies that evaluate the effects of these factors on the risk of 
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developing any one of the BC subtypes.  It has been shown that early parity correlates with 
a reduced risk of TNBC and an increase in the overall survival of the patients (Ma et al., 
2010, Li et al., 2013).  It has also been reported that longer duration of breastfeeding has 
protective effects on TNBC (Li et al., 2013, Sturtz et al., 2014, Ma et al., 2010).   
 
The use of oral contraceptives (OC) has been associated with an increased risk of TNBC. 
Rosenberg and colleagues conducted a prospective follow-up study of the BWHS and 
found that the use of OCs caused a 2.5 fold increase in the risk of TNBC (Rosenberg et al., 
2010).  Others report that longer duration of contraceptive use caused an increase risk, 
compared to women who had never used OCs (Dolle et al., 2009, Beaber et al., 2014, Li et 
al., 2013). However, Turkoz and colleagues conducted a cross-sectional retrospective 
study with 2005 women and discovered that OC, hormone replacement therapy and in vitro 
fertilisation had no significant impact on TNBC outcome and survival, regardless of 
menopausal status (Turkoz et al., 2013). 
 
A great deal of research on the effects of reproductive factors and their association with 
TNBC development and patient prognosis must be undertaken, in order to prevent, treat 
and manage the disease effectively (discussed further below).  
1.1.2.3.4 Anthropometric risk factors 
Research has shown that women with a higher body mass index (BMI) are at a greater risk 
of developing BC. It is thought that the association appears to be driven by distinct 
molecular mechanisms which are based on a woman’s menopausal status (Pierobon and 
Frankenfeld, 2013). In post-menopausal women, upper body obesity is associated with the 
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risk of developing BC. The same cannot be conclusively stated about pre-menopausal 
women (Pierobon and Frankenfeld, 2013). Clinically post-menopausal women often 
present with a less aggressive phenotype and with oestrogen dependent tumours, which are 
most likely driven by steroidal hormones produced by the adipocytes (Rose and Vona-
Davis, 2010).On the other hand, pre-menopausal women who develop BC often present 
with more aggressive tumours that are hormone-independent (Rose and Vona-Davis, 
2010). 
 
Evidence to suggest that obesity is associated with TNBC is contradictory. A retrospective 
study which included 448 TNBC patients found that a higher BMI was more prevalent 
among AAWs, however there was  no  significant difference associated with the disease 
within the three (normal weight, overweight and obese) BMI groups with regards to age at 
diagnosis, menopausal status or pathological tumour stage or grade (Tait et al., 2014). 
Similar findings were observed by Dawood and colleagues, where overweight and obese 
women were predominantly AAW and their height, weight and waist-to-hip ratio were not 
associated with TNBC (Dawood et al., 2012). Moreover a prospective study showed that 
higher BMI is mostly associated with AAWs (Mowad et al., 2013). Although obese 
patients had presented with significantly larger tumours and higher T-stage, recurrence and 
death were not significantly different among the three BM1 groups that were assessed 
(Mowad et al., 2013). 
 
Contradictory to the above mentioned studies, the retrospective study by Turkoz and 
colleagues showed that overweight and obese pre-menopausal women had a significantly 
higher risk of developing TNBC (Turkoz et al., 2013). Another population based case 
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control study which analysed the BMI change of women from the age of 18-44 years 
demonstrated that obesity was associated with increased risk of TNBC among parous 
women only (Kawai et al., 2014).  
 
In a meta-analysis, in which 11 studies were examined, it was discovered that the 
association between TNBC and obesity is dependent on menopausal status (Pierobon and 
Frankenfeld, 2013). In pre-menopausal women a BMI of 30 or more resulted in a 
significant increase risk of developing TNBC; however, in post-menopausal women the 
same BMI did not increase the risk (Pierobon and Frankenfeld, 2013). Looking at the 
studies overall, it is clearly necessary to undertake further research on the role of 
anthropometry and its role in TNBC development together with overall patient survival. 
Moreover further investigations are needed to evaluate the molecular mechanisms that link 
obesity and its relationship with TNBC.  
1.1.2.3.5 Socioeconomic status risk factors  
Socioeconomic status (SES) is intrinsically linked with lifestyle behaviours, including 
physical activity, diet, reproductive experiences, such as having more children and 
screening behaviours, which vary in prevalence across different populations of 
women(Brewster et al., Dunn et al., 2010)  . It has been shown that women with lower 
income brackets are often black and they generally tend to have more children than women 
from more affluent backgrounds (Davies et al., 2013, Sineshaw et al., 2014, Shariff-Marco 
et al., 2014). Also their survival outcome after cancer treatment is lower than that of 
women from a higher income bracket (Shariff-Marco et al., 2014).  
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In a cohort of 1,000 women, it was discovered that of BC patients diagnosed at CHBH, 
those who lived farther away and whom were from low income brackets presented with 
late stage BC diagnosis, compared to their wealthier counterparts (Dickens et al., 2014b). 
Further it was seen that other contributing factors that resulted in delayed diagnosis 
included a lack of education concerning where to go to seek help, poor knowledge of 
symptoms, lack of breast awareness, fear and beliefs held on the causes of cancer and 
whether it is curable (Dickens et al., 2014b). Internationally it has been shown that in 
general women from poor backgrounds or rural areas are most likely to present with more 
aggressive forms of BC, due to lack of access to healthcare (Davies et al., 2013, 
Seneviratne et al., 2015, Newman et al., 2006). In terms of studies concerning the effect of 
low SES on the disease, data from the California Cancer Registry showed that irrespective 
of race or ethnic origin, women living in areas of low SES were more likely than women 
living in areas of high SES to be diagnosed with TNBC than any other type of BC (Parise 
and Caggiano, 2013). 
 
These observations may be one of the contributing factors as to why TNBC is mostly 
prevalent in women AAWs and other African women in other countries.    
1.1.3 Current and novel treatment options 
 At present there are no Food and Drug Administration (FDA) approved drugs for the 
treatment of BC (Andre and Zielinski, 2012). Currently, surgery, radiation and 
chemotherapy are the only treatment options available (Yagata et al., 2011), however, 
some challenges remain (see Figure 1.2). Although chemotherapy is associated with a 
complete pathological response in some patients, other patients do not respond and may 
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relapse often resulting in worse overall survival (Gluz et al., 2009, Cortazar et al., 2014). 
Population based studies on TNBC have shown that the disease is more aggressive than 
other forms of BC(Lee et al., 2014, Yagata et al., 2011).  These studies have also shown 
that there is a higher risk of recurrence within the first three years after initial treatment and 
that the majority of deaths occur within the first five years (Dent et al., 2007, Bayoumi et 
al., 2014, Solin et al., 2009, Pogoda et al., 2013)   (Table 1.2). 
 
Table 1.2: Clinical characteristics of the Triple Negative Breast Cancer phenotype (as 
described by (Dent et al., 2007). 
Often present as interval cancers 
Rapid rise in risk of recurrence following diagnosis 
Distal recurrence rarely preceded by local recurrence 
Increased mortality rate in the first 5years 
Rapid progression from distant recurrence 
Weak relationship between tumour size and node status 
Peak risk of recurrence at 1-3 years 
Local recurrence not predictive of distal recurrence 
Majority of deaths occur in first 5 years 
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Figure 1.2.Schematic representation of a TNBC tumour; the current challenge in its 
treatment and management. A) The normal breast tissue expresses oestrogen receptors (ER, 
green), progesterone receptors (PR, yellow) and human epidermal growth factor-2 receptors (HER-
2, red). B) A TNBC tumour lacks the expression of the hormone receptor and the growth factor 
receptor. C) Endocrine (mauve), radiation (silver) and chemo (blue) therapy are ineffective in 
tumour treatment. D) Ineffective treatment leads to continuous growth. [Diagram was created in 
Microsoft PowerPoint, 2010; Msibi, 2014]. 
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There are many obstacles encountered in the treatment and management of TNBC. These 
include: a lack of targeted therapies, an absence of reliable prognostic and diagnostic 
markers coupled with a poor knowledge of the mechanism of pathology of the disease 
(Podo et al., 2010). These challenges surrounding TNBC have drawn a lot of attention 
from cancer researchers. The mission is to discover and develop novel therapeutics to treat 
and manage the disease effectively.  
 
Novel approaches proposed in the literature include among others, the use of monoclonal 
antibodies (mAb), targeting of angiogenesis, targeting DNA repair and damage 
mechanisms , cell signalling pathways and cancer stem cells (CSCs) (Yagata et al., 2011, 
Koziol et al., 2012, Aulmann et al., 2010, Miki et al., 2014)  . However, thus far none of 
these have been particularly successful. This emphasises the crucial need to better 
understand the mechanisms of TNBC pathogenesis as this will subsequently lead to the 
development of more effective novel therapeutics. In this regard, it is suggested here that 
the Notch signalling pathway is worthy of investigation as a potential therapeutic target. 
The importance of this pathway, and its role in BC development, is described below. 
1.1.4 The Notch signalling pathway  
The elucidation of the Notch signalling pathway began in 1913 when John Smith Dexter 
observed that a mutation of a particular gene in Drosophila ampelophila resulted in the 
development of a notch at the end of the fly’s wings.  Consequently, he called them 
―perfect Notched‖. Subsequently, in 1917, Thomas Hunt Morgan identified the alleles of 
the fly gene now known as NOTCH. The gene was eventually cloned and definitively 
identified during 1985-1986 (Olsauskas-Kuprys et al., 2013, Wharton et al.,  
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1985, Kidd et al., 1986). Since then, research has shown that the pathway is transduced via 
receptor-ligand activation, when neighbouring cells come into contact with one 
another(Kopan and Ilagan, 2009). The pathway is involved in multiple cellular processes, 
including cell fate decisions, tissue homeostasis and stem cell maintenance (Takebe et al., 
2014, Ntziachristos et al., 2014, Bolos et al., 2007) . 
1.1.4.1 The structure of the Notch receptors and their ligands  
1.1.4.1.1 Notch receptors 
There are four trans-membrane Notch receptors in mammals; these being termed NOTCH1 
to 4, (Figure 1.3). The receptors are comprised of 29-36 tandem epidermal growth factor 
like-repeats (EGF) (Kopan and Ilagan, 2009). Many of the repeats are bound to calcium 
that determines the structure and affinity of the receptors to its ligand (Chillakuri et al., 
2012). A negative regulatory region (NRR) that inhibits the activation of the receptor in the 
absence of a ligand follows the EGF repeats (Olsauskas-Kuprys et al., 2013, Chillakuri et 
al., 2012). The NRR region consists of three cysteine-rich Lin12-Notch repeats (LNR) and 
a heterodimerization domain (HD) (Stanley and Okajima, 2010, Chillakuri et al., 2012). 
Together, the repeats and the NRR form the Notch extracellular component (NEC) (Kopan 
and Ilagan, 2009, Chillakuri et al., 2012).    
 
The Notch intracellular component (NIC) is comprised of the recombination signal binding 
protein for immunoglobulin kappa j (RBPjk) association module (RAM) domain that 
contains 12-20 amino-acids (Kopan and Ilagan, 2009). The RAM together with the LNR 
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and HD form the Notch transmembrane (NTM) domain. RAM is also linked to seven 
ankyrin (ANK) repeats by a long and unstructured linker containing one Notch localising 
sequence (NLS) followed by bipartite NLS(Kopan and Ilagan, 2009)  . In the NOTCH-1 
and NOTCH-2 receptor, these are then followed by an evolutionarily divergent 
transactivation domain (TAD); this region is however, absent in NOTCH-3 and NOTCH-4 
(Kopan and Ilagan, 2009, Chillakuri et al., 2012). The TAD is followed by a conserved 
proline/glutamic acid/serine/threonine-rich motif (PEST) which contains degrons that 
regulate the stability of NIC (Chillakuri et al., 2012)  .  
 
1.1.4.1.2 Notch ligands 
There are five ligands, including JAGGED 1 to 2 and DELTA-LIKE 1, 3, and 4, all of 
which are  classified as type 1 transmembrane proteins that belong to the Delta-like and 
Serrate/Jagged families(Stanley and Okajima, 2010). They are characterised by three 
related structural motifs (Chillakuri et al., 2012). The N-terminus consists of a module of 
an unknown structure that is stabilised by a disulphide bond called Module at the N-
terminus of Notch Ligands (MNNL). This module precedes the delta/serrate/lag-2 (DSL) 
motif, which is followed by specialised tandem EGF  repeats known as Delta and OSM-
11-like repeats or DOS(Kopan and Ilagan, 2009) . The DOS is followed by calcium 
binding and non-calcium binding EGF-like repeats; the repeats range in number from 16 
(Jagged family) to 5-9 (delta-family). A cysteine rich domain (CRD) which is only present 
in the Jagged family precedes the EGF repeats. The intracellular component of the ligand 
is a post synaptic density protein (PSD95), Drosophila disc large tumour suppressor 
(Dlg1), and zonula occludens-1 protein (zo-1) Ligand (PDZL) domain that is present only 
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on JAGGED-1 and DELTA-LIKE-1 and 4. This domain facilitates the integration of 
proteins at the adherens junction to promote cell-cell adhesion and inhibit cell motility. 
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Figure 1.3 Diagrammatic representations of the Notch receptor and Notch-ligand. The 
extracellular domain of the receptor is comprised of epithelial growth factor like (EGF) repeats and 
calcium repeats and the negative regulatory region (NRR). The transmembrane domain is 
composed of the lin12-notch repeats (LNR) and heterodimerization (HD) of the NRR and the 
RBPjk Association Module (RAM) component of the notch intracellular component (NIC). The 
intracellular component is comprised of the RAM, ankyrin repeats (ANK), transactivation domain 
(TAD) and proline/glutamic acid/serine/threonine-rich (PEST) domains. The Notch ligand is 
comprised of the module at the n-terminus of notch ligand (MNNL) which precedes the 
delta/serrate/lag-2 (DSL) domain. The domain is preceded by the EGF repeats. These regions all 
form the extracellular domain of the ligand. The Intracellular domain consists of the cysteine rich 
domain and the post synaptic density protein (PSD95), Drosophila disc large tumor suppressor 
(Dlg1), and zonula occludens-1 protein (zo-1) Ligand (PDZL) domain. [Diagram was created on 
Microsoft PowerPoint, 2010; Msibi, 2015] 
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1.1.4.1.3 Notch signal transduction 
The NOTCH receptors (see Figure 1.3) are derived from large (>300 kD) precursor 
polypeptides in the rough endoplasmic reticulum (RER) (Figure 1.4). The precursor 
molecule is subjected to post-translational modifications before reaching maturation. The 
molecule is glycosylated by O-fucose on its EGF repeats. The addition of O-linked Fucose 
is mediated by O-fucosyl transferase 1. The NOTCH precursor is then transported to the 
trans-Golgi apparatus by the guanosine triphosphate hydrolase (GTPase) Rab-protein 6. 
There, the O-fucose is extended by the addition of carbohydrate chains on the serine and 
threonine residues, the elongation is mediated by the fringe family, specifically the β1, 3-N 
acetylglucosaminyl-transferases Lunatic, Manic or Radical. 
 
 The modification by the fringe proteins controls the ligand-mediated activation. The fully 
modified Notch pre-protein then experiences its first of three proteolytic cleavages in the 
Golgi. A Furin-like convertase (at site 1) (Figure 1.4) creates the first cleavage at the N and 
C terminus of the protein which forms the mature NOTCH receptor. The receptor is then 
transported to the plasma membrane where it interacts with its membrane-associated ligand 
(Figure 1.4). Upon ligand-receptor engagement, a second cleavage is initiated by a 
disintegrin metalloproteases 10 and 17 (ADAM 10 and ADAM 17, respectively) (at site 2) 
(Figure 1.4). which releases the NEC to be trans-endocytosed into the ligand-expressing 
cell. This then leaves NTM vulnerable to the third and final cleavage by Gamma-secretase 
(γ-secretase) (at site 3) (Figure 1.4) complex, liberating the NIC. The component is then 
trans-located into the nucleus where it forms a transcriptional activated complex with the 
following:  DNA-binding factor, C-promoter binding factor-1(CBF-1), a constitutive 
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transcriptional repressor, a displacing co-repressor and recruiting co-activators such as 
Mastermind-like (MAML) (Figure 1.4). Formation of these complexes results in the 
expression of various NOTCH target genes, such as HES/HEY family genes and C-MYC, 
which are involved in cell growth, differentiation, and survival (Figure 1.4).   
 
Notch activates many genes associated with cell differentiation and/or survival. Following 
receptor-ligand binding, NIC bound to CBF-1 in the nucleus at the time of receptor 
activation is marked for proteosomal degradation by the E3 ubiquitin ligases Numb and 
Itch. The deregulation of this pathway is associated with cancer and developmental 
disorders.  
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Figure 1.4 A Schematic representation of the Notch pathway. Notch precursor protein is 
glycosylated in the rough endoplasmic reticulum (RER) and transported to the Golgi-apparatus 
where it is cleaved by Furin-like convertase (S1). This cleavage results in a mature NOTCH 
receptor being placed on the plasma membrane where it awaits ligand activation.  A Disintegrin 
Metalloprotease (ADAM) makes the second cleavage causing receptor vulnerability to cleavage by 
gamma secretase (γ-secretase) (S3). The third cleavage results in the generation of the notch 
intracellular component (NIC), which is translocated into the nucleus where it binds with C-
promoter binding factor-1 (CBF-1), thus repressing or activating target gene expression such as 
HEYS/HES;C-MYC;P21;BCL-2;CYCLIN D1 [Diagram was created in Microsoft PowerPoint, 
2010; Msibi; 2015].  
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1.1.5 Notch signalling in breast cancer 
The earliest indication that Notch signalling plays a role in human carcinogenesis was 
observed in 1991 in T-cell acute Lymphoblastic Leukaemia/Lymphoma (T-ALL) (Ellisen 
et al., 1991). It was found that the NOTCH-1 chromosomal translocation t(7;9)(q34;q34.3), 
which is responsible for producing NRR, was altered thus causing  defects in the 
signal(Ellisen et al., 1991).Subsequently, NOTCH-1 gain-of-function mutations were 
discovered in approximately 50% of T-ALL and in other haematologic cancers (Aster et 
al., 2011).Furthermore, aberrant NOTCH signalling has been detected in many solid 
tumours for example, cervical, colon, liver, lung, pancreatic, prostate, ovarian and renal 
cancers(Rose et al., 2010, Wang et al., 2010, Du et al., 2012, Yong et al., 2011, Gao et al., 
2014, Theys et al., 2013, Shao et al., 2012) . Of particular interest here is the function of 
the Notch signal in BC development. 
Evidence that Notch receptors are possible breast oncogenes was first seen in experiments 
conducted on mice, where activation of NOTCH-1 and NOTCH-4 via mouse mammary 
tumour virus induced neoplasms.  Moreover, the up-regulation of NOTCH-4 resulted in the 
transformation of mammary epithelium in vitro and in vivo (Farnie and Clarke, 2007). In 
humans, the first direct correlation of dysregulated Notch signal and breast malignancy 
was published by Reedijk et al. in 2005 (Reedijk et al., 2005).Using 
immunohistochemistry, the group’s findings suggested that high expression of the 
NOTCH-1 receptor, together with the ligand JAGGED-1, correlated with poor BC 
prognosis and overall survival. They also noted that the overexpression was more 
prominent in ER negative tumours than ER positive ones (Reedijk et al., 2005). In an 
independent study by Dickson and colleagues, the expression of miRNAs was evaluated 
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using in-situ hybridisation (Dickson et al., 2007). Their findings verified those obtained by 
Reedijk and colleagues, as they were able to show that high levels of JAGGED-1 
correlated with a lower five year survival rate in BC patients (Reedijk et al., 2005) . These 
data were reinforced by Speiser et al. (2012) who demonstrated that TNBC tumours 
express high levels of NOTCH-1 and NOTCH-4. However; their study did not prove that 
high expression levels of these receptors are correlated with poor clinical outcome (Speiser 
et al., 2012). The limitation of their study was a small sample size of 50 tumours. 
 Research on NOTCH-2 and NOTCH-3 is scarce, with approximately two studies that 
directly investigated the role of NOTCH-2 in human BC and only one study that 
investigated NOTCH-3. In 2004, Parr et al. suggested that NOTCH-2 activation increased 
tumour survival and that tumours expressing higher levels of this receptor were well 
differentiated compared those that expressed NOTCH-1(Parr et al., 2004). The tumour 
xenografts from ER negative cells displayed slowed growth when NOTCH-2 was up-
regulated (O'Neill et al., 2007).  These data imply that NOTCH-2 is a tumour suppressor 
gene in the breast.  
Yamaguchi and colleagues reported that in HER-2
 
negative
 
BC cell lines, down-regulation 
of NOTCH-3 resulted in suppressed proliferation and increased apoptosis (Yamaguchi et 
al., 2008). Evidently, Notch signal activation appeared to be a ―double edged sword‖ 
where it can either exert oncogenic or tumour suppressive effects depending on the 
receptor that is activated (Capaccione and Pine, 2013, Roy et al., 2007, Lobry et al., 2014). 
However, the role that the Notch signal plays within each BC subtype remains unclear 
since most of the available data relates to ER positive BC. Moreover, the relationships 
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between ER, PR, HER-2 and Notch are uncertain as data is limited. It has however been 
suggested that oestrogen plays a role in the regulation of Notch signalling.  
This notion was extrapolated from a study by Rizzo et al. (2009) (Rizzo et al., 2009). They 
reported that oestrogen deprivation of the ER
 
positive cell line Michigan Cancer 
Foundation – 7 (MCF7) resulted in increased NOTCH-1 activity (Rizzo et al., 2009). 
Osipo et al. (2008) demonstrated that HER-2 overexpressing cells had low Notch 
transcriptional activity compared to HER-2 negative cells (Osipo et al., 2008). 
Subsequently, in 2009, Korkaya and Wicha suggested the following concerning the 
relationship between HER-2 overexpression and Notch pathway activity (Korkaya and 
Wicha, 2009):  
1. The HER-2 promoter contains Notch binding sequences 
2. HER-2 overexpressing cells display activated Notch signal 
3. Inhibition of the Notch signal using an siRNA or γ-secretase inhibitors results in 
the down-regulation of HER-2 expression, resulting in decreased mammo- sphere 
formation  
In the same year, Graham et al. (2009) demonstrated that in normal breast cells, 
progesterone increased the expression of DELTA-LIKE 1 and 3 ligands which showed that 
a lack of progesterone may decrease the activity of the Notch pathway(Graham et al., 
2009).  Other factors that may influence Notch pathway activity include hypoxia and cross 
talk with other pathways such as WNT, Sonic hedgehog and Ras(Kikuchi et al., 2011, Han 
et al., 2011). Taken together, the literature shows that aberrant Notch signalling has 
tumourigenic effects on the breast, and that additional data is required in order to 
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understand its function in TNBC. Supplementary data may add to the rationale to target 
Notch signal as a therapeutic strategy in treating TNBC, as this cancer currently lacks FDA 
approved agents. 
1.1.6 Strategies to target Notch signal pathway in Triple negative breast cancer 
As there is a lack of targeted therapeutic agents for treating TNBC, and that there is strong 
evidence suggesting that the aberrant Notch signalling pathway is a key event in the 
aetiology of BC, targeted therapies aimed at modulating the pathway in TNBC are 
emerging.  In 2008, Rizzo, et al. rationalised targeting the pathway based on the reasons 
mentioned below: 
 Firstly, as the cascade is triggered by a receptor-ligand interaction that does not 
require an enzymatic amplification step, the ―signal intensity‖ can be modulated 
very precisely by cellular regulatory mechanisms. Therefore, the downstream 
effects of Notch activation are exquisitely dose dependent (Rizzo et al.,2008b) . 
Furthermore, complete shutdown of the pathway may not be necessary to achieve a 
therapeutic effect.  
 Secondly, the intracellular half-life of the active form Notch is generally very short 
and-  
 Thirdly, the effects of Notch are remarkably context dependent as each receptor 
exerts a different effect on the breast cells.   
There are three main strategies to modulate the signal proposed as treatment options in 
TNBC, including the administration of mAbs, short interfering RNAs (siRNA) and γ-
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secretase inhibitors (GSI) (see Figure 1.5); and  each of  these approaches are explained 
below. 
1.1.6.1 Notch1 and Delta-like 4 monoclonal antibodies  
The overexpression of NOTCH receptors and ligands makes mAb therapy an attractive 
treatment option, as they are effective in eliminating tumour cells and have a low toxicity 
profile (Shuptrine et al., 2012). Furthermore, mAbs are designed to target tumours through 
specific or associated antigens, without the need for hepatic metabolism. An ideal example 
of a successful mAb in BC therapy is Trastuzumab which is administered to patients with 
ER positive BC, in combination with chemotherapy. Attempts to address the potential use 
of Notch mAbs have been made by a few research groups. 
 Qui and collegues, developed neutralising antibodies against human NOTCH-1(Qiu et al., 
2013). They found that inhibiting the pathway with mAbs resulted in decreased expression 
of NOTCH-1 signal target genes in ER negative BC cells (Qiu et al., 2013). They also 
reported that blocking the signal enhanced the anti-tumour efficacy of Docetaxel. Sharma 
and colleagues characterised and determined the effects of several mAbs on ligand binding 
and consequent receptor activation (Sharma et al., 2012). They observed that a mAb 
specific to the EGF repeats 11 to 12, appeared to be the most effective in inhibiting 
JAGGED-1 and DELTA-LIKE-4 binding to the NOTCH-1 receptor (Sharma et al., 2012). 
Subsequently, these antibodies reduced the CSC population present in BC cell lines, as 
well as the expression of NOTCH-1 target genes. Since breast tumours co-express NOTCH 
receptors, mAb therapy is highly attractive, as a specific receptor and/or receptors may be 
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targeted effectively, eliminating the need to ―shut down‖ the entire pathway. Currently, the 
use of Notch mAbs for the treatment of TNBC has not been used in clinical trials.  
1.1.6.2 Notch-1 siRNA 
RNA interference (RNAi) is an evolutionary conserved post-transcriptional gene-silencing 
pathway that was first discovered in the nematode (Fire et al., 1998). It may be modulated 
by double stranded RNA (dsRNA) molecules which are 21-23 nucleotides in length, and 
are referred to as short interfering RNAs (siRNAs) (Karagiannis and El-Osta, 2005)  .  
Briefly, double stranded (dsRNA) is cleaved into siRNAs by the enzyme dicer and its 
associated proteins. One strand, the guide strand, is integrated into the RNA induced 
silencing complex (RISC), whereas the other strand is subjected to degradation. The guide 
strand binds to a complementary mRNA which triggers its degradation by RISC.  
 
The siRNAs are designed to interfere with the expression of specific genes, to ultimately 
knock-down gene expression. The knock-down of NOTCH-1 or NOTCH-4 has strong anti-
proliferative effects in BC cell lines (Rizzo et al., 2008a). Zang and colleague reported that 
down-regulating the expression of the NOTCH-1 receptor results in an increase in chemo- 
sensitivity (Zang et al., 2010). These results show that siRNA may be a promising target 
for BC treatment.  However, the tissue and organ specific delivery; of siRNAs remains a 
challenge. The central considerations include chemical modification and delivery strategy; 
and here as appropriate chemical modifications help siRNA duplexes avoid immune-
stimulation and allow them to withstand degradation from nucleases. However, efficient 
and tissue specific delivery may be the biggest challenge in the application of siRNA to 
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humans. To date, there are no clinical trials that have utilised NOTCH siRNAs in BC 
patients. 
1.1.6.3 ƴ-Secretase inhibitors 
Ƴ-secretase is an intramembrane aspartyl protease with a molecular weight of 
approximately 230 kiloDaltons (Wolfe, 2009, Lu et al., 2014). This is composed of four 
subunits those are: Nicastrin, presenilin enhancer 2 (PEN2); presenilin; and anterior 
pharnx-defective 1(APH1) (Golde et al., 2013). It cleaves more than 30 type 1 
transmembrane proteins within their membrane spanning regions (Lu et al., 2014, Tolia 
and De Strooper, 2009)   and these cleaved products serve as signalling molecules. This 
process is known as regulated intramembrane proteolysis (RIP) (Lu et al., 2014). Two of 
its most extensively studied substrates are the amyloid precursor protein and the NOTCH 
receptors (Lewis et al., 2003, 2014, Kim et al., 2004). Other substrates include HER-2, 
epithelial cadherin (E-cadherin), Neural cadherin (N-cadherin), CD44, Nectin-1 and the 
low density lipoproteins receptor (Wolfe, 2009). In the Notch pathway, it participates in 
the final cleavage of the NOTCH receptor resulting in a NIC which is translocated to the 
nucleus where it activates target gene expression (see Figure 1.4). Inhibiting this cleavage 
step with small molecules could prove beneficial as it has previously been demonstrated 
that targeting Notch with GSI suppressed survivin levels, induced apoptosis, abolished 
colony formation of BC cells on soft agar and inhibited metastatic tumour growth in mice 
(Lee et al., 2008b). Furthermore, other studies have shown that cell proliferation decreases 
with GSI treatment in ER
 
negative cell lines (Han et al., 2009, McClements et al., 2013, 
Wang et al., 2010). 
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GSIs are divided into the following three classes: peptide isosteres, azepines and 
sulphonamides.  They may further be classified as Type 1 and 2 depending on their 
structure and binding site (Olsauskas-Kuprys et al., 2013). Type 1 GSIs are transition-state 
analogues, peptide isosteres that mimic the transition state of a substrate’s cleavage by γ-
secretase and competitively bind to the catalytic active site of presenilins (Olsauskas-
Kuprys et al., 2013). Type 2 GSIs are small non-transitional-state inhibitory molecules that 
bind non-competitively to a site other than the active site, possibly at the interface of the γ-
secretase complex dimer (Olsauskas-Kuprys et al., 2013). These inhibitors target all four 
NOTCH receptors, as well as other substrates; these side interactions may result in 
gastrointestinal toxicities (Takebe et al., 2014, Espinoza and Miele, 2013). However, it has 
been shown that glucocorticoid administration protects against GSI-induced gut toxicity, as 
they antagonise the effects of NOTCH receptor inhibition in the intestinal epithelium. Thus 
combining GSIs and glucocorticoids may improve the safety of GSIs when treating human 
cancers (Wei et al., 2010)  .   
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Figure 1.5 Potential Therapeutic targets for Notch in Triple negative Breast cancer. . The 
pathway may be targeted by either: inhibiting receptor-ligand binding with monoclonal antibodies, 
which would prevent activation of specific genes depending on which of the four receptors or five 
ligands are targeted. Site2 (S2) may be blocked with mAb; siRNA. Site (S3) may be inhibited with 
gamma secretase inhibitors. [Diagram was created on Microsoft Powerpoint 2010 (Msibi, 2015)]. 
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1.2 Experimental approach and rationale 
In view of the current literature on the Notch signal pathway and its association with 
TNBC, it is valid to further investigate its effects on the manifestation and progression of 
the disease.  
 
Differences between Notch signalling in TNBC and Notch signalling in receptor positive 
BC since as mentioned earlier majority of the research has been aimed at receptor positive 
BC and there is also the thought that absence of oestrogen intensifies the signal. The 
methodological approach applied in this study is briefly discussed below. 
1.2.1 Experimental approach 
To interrogate the effects of the pathway on TNBC, an in vitro approach will be employed. 
Receptor negative cells that represent TNBC will be evaluated in comparison with receptor 
positive cells which represent hormone sensitive BC. The receptor positive cells are treated 
as the control group while the receptor negative group is treated as the experimental group. 
1.2.1.1 Notch pathway inhibition 
The pathway will be evaluated by inhibiting the pathway with pharmacological inhibitors 
N-(N-3,5-Diflurophenacetyl-L-alanyl)-S-phenyl glycine t-Butyl Ester (DAPT) and N-
[(1S)-2-[[(7S)-6,7-Dihydro-5-5methyl-6-oxo-5H-dibenz[b,d] azepin-7-yl]amino-1-methyl-
2-oxoethyl]-3,difluorobenzeneacetamide (DBZ). Although both are classified as an 
azapines, they represent a non-transitional state analogue and a transitional state analogue 
(a competitive and non-competitive inhibitor) respectively. 
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1.2.1.2 Cellular proliferation and viability 
The effects of Notch pathway inhibition on cell proliferation and viability of the cell lines, 
in response to pharmacological inhibition will be evaluated by cell impedance assays, 
using the xCELLigence (Roche Diagnostics, ACEA Biosciences Inc., USA) real time cell 
analyses (RTCA), hereafter referred to as xCELLigence assays.  
 
The xCELLigence (Roche) instrument is a microelectronic biosensor system that monitors 
cell behaviour in real time, by measuring the resistance which is conferred by cells as they 
attach and spread on electronic plates (E-plates). The E-plate consisting of 16 individual 
wells has gold electrodes at the base of each well, that sense resistance. This resistance is 
referred to as impedance, which is defined as the measure of the total opposition to the 
electric current flow in an alternating current circuit, made up of two components: the 
ohmic resistance and reactance (Figure 1.6).  To quantify the status of cells based on 
impedance, a parameter termed the Cell Index (CI) is derived according to the equation: CI 
= max (Rcell (fi) / Rb(fi) – 1)  i= 1,….N; where Rb(f) and Rcell represents the frequency-
dependant electrode resistances with cells and without cells respectively; and N represents  
the number of the frequency points at which the impedance is measured. Thus the CI is a 
quantitative measure of the overall status of the cells in a particular well, wherein an 
increase in the number of cells that attach and spread on the electrode surface confers an 
increase in the CI.  There are several advantages of this technology compared to so-called 
end-point assays (see Figure 1.6 below): 
That it is a label-free detection system, resulting in minimal interference with normal cell 
function.  
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Since measurement is read in real time, the physiological effects of any compound can be 
assessed immediately as compared to an end-point assay, where cells are usually harvested 
and results are read after a certain amount of hours (Figure 1.7). 
 
It can be used to gather information on different cellular processes, such as, cell 
proliferation, migration, compound-mediated cytotoxicity, apoptosis, and real-time 
detection of viral cytopathic effects, cell adhesion, cell viability and proliferation. 
 
The main disadvantage of this system is that it expensive and thus other simple assays are 
applied to first optimise compound concentrations. In the present study the alternative 
assay used to test drug concentrations was the Trypan Blue (TB) exclusion dye assay - a 
classical end-point assay (see Figure 1.7 below).  
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Figure 1.6 A diagrammatic representation of the cell-electrode interaction in an E-plate. 
Impedance increases as cells attach and divide. Panel A) as there are no cells attached to the gold 
electrode there is therefore no resistance to the electrical current (arrows) flowing through the 
electrode. As one cell attaches, the current decreases; and as two cells attach and spread there is a 
further decrease in current. Panel B) The impedance (resistance) equals zero as there are no cells 
attached to the electrode; as a cell attaches the resistance is increased and doubles when two cells 
attach. The impedance is further increased by the strength of cell attachment to the electrode. 
[Diagram was created on Microsoft Powerpoint, 2010; Msibi, 2014] and was adapted from 
www.Roche.com. 
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The TB exclusion assay is a simple and inexpensive test that is used to determine cell 
viability. TB is impermeable to live cell membranes, a property that is exploited by this 
assay. The live cells (viable) will exclude the dye, whereas dead cells (non-viable) take it 
in.  Essentially, a cell suspension is produced and cells treated with TB are counted in a 
haemocytometer viewed under a microscope, allowing for the calculation of the percentage 
of viable (unstained cells) and non-viable (stained) cells. The TB assay thus provides for 
an effective test to assess drug concentration in relation to cell viability. A schematic 
representation of end-point versus real time assays is shown below (see Figure 1.7). 
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Figure 1.7 Schematic diagrams showing the difference between classical endpoint assay and 
the xCELLigence RTCA technology. In a classical end-point assay there is a period termed the 
―black box‖ in which the physiological effects of the inhibitor can’t be monitored or collected. Data 
is only gathered after cell harvesting. In the xCelligence-RTCA system, there is no ―black box‖, 
and cells may be monitored and data evaluated in real-time. [Diagrams were created on Microsoft 
Powerpoint, 2010; Msibi, 2014]. 
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1.2.1.3 Evaluating cell morphology and migration 
Morphology and migration will be assessed by fluorescence and immunofluorescence 
microscopy, specifically by monitoring alterations in the expression of the F-actin 
cytoskeleton and the cell adhesion protein, E-cadherin. The F-actin cytoskeleton is critical 
for cell motility, cell division, organelle movement, cell signaling and the establishment 
and maintenance of cell junctions and cell shape (Doherty and McMahon, 2008). As the 
cytoskeleton maintains the integrity of the cell its disruption can cause cellular arrest, as 
well changes in the cell shape can interrupt communication amongst cells (Heng and Koh, 
2010). The result is that any pathway that is dependent on paracrine signaling may become 
aberrant.  
 
E-cadherin is a homophilic cell-to-cell adhesion protein localized to the adherens junctions 
of all epithelial cells (Kalluri and Weinberg, 2009). Its cytoplasmic domain effectively 
creates a bridge between the cytoskeleton of adjacent cells by interacting with both cortical 
actin filaments and the microtubule network (Yilmaz and Christofori, 2009). Amongst its 
different functions it also serves as a tumor suppressor protein (Baranwal and Alahari, 
2009).. Loss of E-cadherin results in invasion and migration therefore in this study the 
presence of the protein will be used as a marker for migration potential of the cells, that is 
cells that express the protein should be less invasive than those that do not.  
The migration potential of each cell line will be assessed by employing the scratch assay. 
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1.2.2 Rationale 
Determining the effects of Notch signalling on these aspects of cellular function, will 
provide an insight into the probable role that the signal plays in TNBC tumour progression. 
Additionally, while it has been shown that oestrogen inhibits Notch activity, there is 
however little evidence to support this.  Investigating the role of Notch inhibition in TNBC 
versus ER positive BC, would improve our understanding of its functional role in TNBC 
development. This would allow for the development of novel therapeutics that specifically 
target the modulatory components of the Notch signalling pathway in patients with TNBC. 
Here, the potential role of Notch signalling is queried in TNBC and more specifically, its 
validity as a therapeutic target.  
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1.2.2.1 Aims and objectives 
1.2.2.1.1 Aim 
To evaluate the functional role of the Notch signalling pathway in triple negative (hormone 
insensitive) breast cancer cell lines. 
 1.2.2.1.2 Objectives 
1. Profile the cellular growth of the hormone sensitive Michigan Cancer Foundation – 
7 (MCF7) breast cancer cell line, relative to the hormone insensitive M.D 
Anderson- Metastatic Breast -231 (MDA-MB-231) and M.D Anderson-Metastatic 
Breast-436 (MDA-MB 436) cell lines, using cell impedance assays. 
2. Determine the effects of pharmacological inhibition on cell growth patterns in the 
aforementioned cell lines, using cell impedance assays 
3. Determine the protein expression of NIC and E-cadherin pre- and post- 
pharmacological inhibition of the Notch signal.  
4. Determine the effects of Notch signal inhibition on cell migration using scratch 
assays. 
5. Determine the effects of Notch signal inhibition on the F-actin cytoskeleton. 
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CHAPTER 2: MATERIALS AND METHODS 
The overall summary of the experimental approach used here is presented in the diagram 
below (Figure 2.1). 
Tissue culture maintenance of hormone sensitive MCF-7, hormone 
insensitive MDA-MB-231 and MDA-MB-436 cell line. In appropriate media
Growth profiling with xCelligence 
Notch pathway inhibition by gamma secretase inhibitors DAPT and DBZ
 Confocal Microscopy
Data analysis. Statistics  Non parametric tests one-way ANOVA, Kruskal Wallis 
test
Proliferation assay with 
xCelligence
Migration assay
 
Figure 2.1. Flow diagram representation of methodology applied in this study. Cell lines were 
cultured and maintained in appropriate conditions. Thereafter their normal growth patterns were 
monitored in real time using cell impedance assays (xCELLigence, Roche). Cells were treated with 
the pharmacological gamma secretase inhibitors, N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-
5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,difluorobenzeneacetamide (DBZ) and 
N-(N-3, 5-Diflurophenacetyl-L-alanyl))-S-phenyl glycine t-Butyl Ester (DAPT), respectively.  
The subsequent pharmacological effects on cell proliferation, migration, and protein expression 
were assessed by each of xCelligence, scratch/migration assays and confocal microscopy, 
respectively. All data was analysed using Graph Pad Prism v5. Non-parametric tests, including 
One-way ANOVA and the Kruskal Wallis test were used for statistical analyses. Detailed protocols 
are in appendice A. [Diagram was created on Coreldraw version 12 (Msibi 2014)]. 
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2.1 Mammalian cell lines and cell culture maintenance 
As mammalian cell culture utilising commercially acquired cell lines were used to study 
the Notch pathway in vitro, human ethics clearance was not required (see ethics waiver-
Appendix B.5). 
2.1.1 Cell lines 
All cell lines were procured from the American Type Cell Culture (ATCC, USA). A 
hormone sensitive BC cell line, MCF7 and two hormone insensitive BC cell lines, MDA-
MB-231 and MDA-MB-436 were utilised in this study. These cell lines are described 
below and are summarised in Table 2.1: 
 The MCF-7 cell line is an invasive ductal adenocarcinoma breast cell line, 
originally isolated from a metastatic site via pleural effusion in 1970 from a 69 
year-old female Caucasian (Holliday and Spiers, 2011, Soule et al., 1973). In the 
present study it was used as the control group because it expresses ER, PR and 
HER-2 (which is not overexpressed)   
 Both the MDA-MB-231 and MDA-MB-436 cells are invasive ductal 
adenocarcinoma breast cell lines, which were isolated from a metastatic site via 
pleural effusion from 51-year old and 43-year old female Caucasians, respectively 
(Brinkley et al., 1980, Chavez at al., 2010). Here they were used as the 
experimental group, since they lack ER, PR and HER-2 and thus represent TNBC. 
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 Table 2.1: A summary of the characteristics of the breast cell lines. 
Cell line Hormone receptor status  Ethnicity   Age Phenotype Group 
MCF-7 ER+ PR+  HER-2 + (not 
overexpressed) 
Caucasian 69 Luminal 
epithelial 
control  
MDA-
MB-231 
ER-.PR-,HER-2- Caucasian 51 Basal 
epithelial 
experimental 
MDA-
MB-436 
ER-,PR-,HER-2- Caucasian 43 Basal 
epithelial 
experimental 
 
2.1.2 Cell culture maintenance 
The cell lines mentioned above were grown and maintained in cell culture flasks (SPL-Life 
Sciences) and were incubated at 37  C in 5% CO2  (ThermoForm series ll water jacketed 
CO2 Incubator [HEPA FILTER]). The MCF-7 and MDA-MB-231 cell lines were grown in 
DMEM-F12 (#BE12-719F, Biowhittaker® Lonza,USA) medium supplemented with 10% 
(v/v) foetal bovine serum (FBS) (#SV30160.03, HYCLONE®, USA) and 1% (v/v) 
antibiotic penicillin/streptomycin (#17-602E, Biowhittaker
® 
Lonza, USA). 
 The MDA-MB-436 cell line was cultured in Leibovitz media (L-15) (#BE12-700F, 
Biowhittaker® Lonza,USA), supplemented with 10% (v/v) FBS, 0.1% (v/v) human insulin 
(#19278,Sigma Life Sciences, USA), 0.08% L-glutamine (#G7513, Sigma Life Sciences, 
USA) and 1% (v/v) antibiotic penicillin/streptomycin (#17-602E, Biowhittaker 
® 
Lonza, 
USA). Cell growth media was changed every 3 days and confluency was monitored with 
an inverted phase contrast microscope (Carl Zeiss Axiovert 25). 
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2.2 Analysis of cellular proliferation  
2.2.1 Normal growth curve profiling 
As a first approach, normal growth signatures of each cell line were monitored with 
xCelligence-RTCA (Roche) both to assess individual differences in growth patterns and to 
compare the growth patterns of TNBC cell lines versus the hormone sensitive cell line. 
Cells were grown in culture flasks until they reached 80% - 90% confluence. They were 
then trypsinized to create a single suspension and counted using an automated cell counter 
(Bio-Rad) (see Appendix B.1 and B.4). The cell count for each cell line was adjusted to an 
optimised seeding density (see Table 2.2 and optimisation in Appendix C.1). 
Table 2.2: Optimised cell seeding density for xCelligence studies.  
CELL LINE SEEDING DENSITY cells/ml 
MCF-7                    10000 
MDA-MB-231                      5000 
MDA-MB-436                      5000 
 
 A volume of 100µl of culture medium, appropriate to the particular cell line, was added 
into each well of a 16–well E-plate (ACEA, San Diago). Prior to initiating an experiment, 
with the addition of cells, a reading of this complete drug-free medium was taken as a 
background scan; this was done for 1min. Thereafter 100µl of cell suspension was added to 
each well and mixed thoroughly with the medium to give a final volume of 200µl per well. 
The E-Plates were incubated at 37  C and 5  CO2   to allow cells to adhere to the bottom of 
the well surface for 45mins, as advised by Roche. Thereafter the plates were inserted on 
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the instrument’s docking port and the monitoring system was set to record readings every 
30mins for a total of 200hrs.  
2.2.2 Cell viability and proliferation assays 
To determine the effects of Notch pathway inhibition in BC cells, two γ-secretase 
inhibitors , DAPT (#D5942-5mg; Sigma Life Sciences) and DBZ (Tocris Biosciences, 
Bristol UK) were evaluated. Dimethyl Sulfoxide (DMSO) was used to dissolve the 
lyophilised form of the inhibitors and thus was included here as the vehicle control at 
0.2%. The xCELLigence (Roche) instrument was employed to assess the effects of each 
inhibitor on the cell proliferation and viability. In addition the TB exclusion-dye assay was 
performed for the purposes of comparing it to xCelligence cell viability data and to 
optimise inhibitor concentrations.  
2.2.2.1 xCelligence-proliferation and viability assay   
All the steps of the normal growth profiling assay were followed, as described above. Cells 
were cultured in complete medium for 22-24 hours; and then wells of the E-plates were 
rinsed 3 times with 200µl of Phosphate Buffered Saline (PBS) (# P4417-100TAB; Sigma 
Life Sciences). Next 200µl of serum-free media was added to each well. The addition of 
serum-free media was done for the purpose of serum starvation, a process that arrests cells 
in G1/G0 phase of the cell cycle (Weinberg and Lundberg, 1999). Synchronizing the cells 
at the same phase of the cycle allows them to re-enter the cycle, once they are cultured 
again with serum containing medium. 
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Following serum starvation, wells were rinsed once with PBS and then 200ul of complete 
medium containing either 20µM of DAPT, 20µM DBZ, 20µl DMSO (vehicle control) or 
complete drug-free medium (untreated control) was added to the wells. The plates were 
incubated at 37  C in 5% CO2 in air for 48 hours, with impedance readings being recorded 
every 30mins. 
2.2.2.2 Trypan blue exclusion cell viability assay 
In the TB exclusion assay cells were grown in 12 well cell culture plates (SPL Life 
Sciences), at a seeding density of 2 x 10
3 
cells/well. After 22-24 hours, the cells were 
rinsed 3 times with 1ml of sterile PBS. After this, 1ml of serum-free media was added to 
each well, to serum starve for 18-20 hours. Following serum starvation, wells were washed 
once with PBS, then 1ml of complete medium containing one of either 20µM of DAPT, 
20µM DBZ, or 20µl DMSO (vehicle control) was added. In the case of untreated controls, 
complete drug-free media (untreated control) was added to wells. Then cells were 
incubated at 37  C in 5% CO2 in air for 48 hours. Thereafter the wells were rinsed 3 times 
with PBS, and the cells were trypsinized with 200µl of trypsin/EDTA for 3mins. After 
neutralizing the trypsin solution with complete medium, the cells were pelleted by 
centrifuging in 1ml Eppendorf tubes at 800rpm for 3mins; the supernatant was discarded 
and the cell pellet was re-suspended in 200µl of serum-free media to prepare for cell 
counting (TB binds to serum proteins, hence the use of serum-free media).  Thereafter 10ul 
of TB was mixed with 10ul of cell suspension, making a 20ul mixture and 10ul of this 
mixture was loaded onto the haemocytometer. Cells were counted and viability was 
calculated by the formula: Percentage viability = [1.00 – (Number of non-viable cells ÷ 
Number of total cells)] × 100 
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2.3 Confocal immunofluorescence microscopy 
The immunofluorescence staining technique makes use of antibodies to locate and identify 
the expression patterns of proteins in cells. A primary antibody will bind specifically to an 
antigen and a secondary antibody conjugated to a fluorochrome then binds to the primary 
antibody (Fritschy and Härtig, 2001). This binding allows for the detection of the target 
protein. When the fluorochrome absorbs high energy light it is excited and fluoresces at its 
characteristic emission wavelength, thus making it possible to detect the antibody-antigen 
complex (Fritschy and Härtig, 2001). The fluorescent proteins are viewed with a 
fluorescence microscope. There are different types of fluorescence microscopes and here a 
confocal scanning laser microscope was used. A confocal microscope (Figure 2.2) 
provides high resolution images and three dimensional reconstructions of specimens, and 
enables the co-localisation of two or more proteins on the same specimen.  
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Figure 2.2. Principal of the confocal laser microscope. Light from a laser beam passes through 
the aperture, whereupon this light is then focused by the objective lens into the surface of a 
specimen. The reflection from the specimen passes back through the objective lens. The beam 
splitter separates a portion of the light. The light passes through the pinhole into the photomultiplier 
that then detects the intensity of the light. The light signal is transformed into an electrical signal 
that is read by the computer. [Diagrams were created on Microsoft Powerpoint 2010 (Msibi 2015)]. 
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Here, the cellular expression and localisation of NIC and E-cadherin proteins within each 
cell line were assessed. Also, possible changes in cellular morphology were evaluated 
following treatment with the Notch inhibitors. 
2.3.1 Immunofluorescence staining   
2.3.1.1 Cell preparation 
Cells were grown in appropriate media on sterile glass coverslips in 6 well culture plates 
(SPL Life Sciences) and were allowed to reach 50% confluence. Once the required cell 
confluence had been reached, cells were rinsed in PBS and medium was replenished with 
serum-free medium. This allowed for serum starvation which was done for 18-20hrs. 
Following this, cells were treated with complete medium containing 20µM DAPT, 20µM 
DBZ or 20µl of DMSO (vehicle control), or treated with complete medium alone 
(untreated control) and were incubated for 48 hours at 37  C in 5% CO2 in air. 
After the 48 hour incubation period, the cells were rinsed 3 times with 1ml of PBS; then 
fixed for 15mins in an incubator at 37  C  in pre-warmed 3% PBS-formaldehyde solution 
(Appendices A.1.3) and were subsequently rinsed 3 times with 1ml of PBS.   
In order to allow for intracellular staining and to block non-specific antibody binding, the 
cells were permeabilized with warm PBS-BSA (Santa Cruz Biotechnology) containing 
Triton X-100 (Appendix A.1.4) for 5mins at room temperature (RT). Triton X-100 is a 
detergent that permeabilizes cell membranes, whilst BSA binds antigenic sites and blocks 
non-specific antibody binding. After permeabilising, the cells were rinsed 3 times with 
PBS to remove excess Triton X-100.  
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2.3.1.2 Primary and Secondary antibody staining  
The cells were incubated overnight at37  C with 100µl of the following primary antibodies: 
rabbit-Anti-Notch-1 intracellular component domain (#07-1231; Merck Millipore) or 
purified mouse anti-E-cadherin (#610181; BD Transduction Laboratories ™) optimally 
diluted at 1:200 and 1:2500, respectively in warm PBS-BSA buffer. An additional negative 
control was to include the primary antibody incubation step, but to exclude the secondary 
antibody, substituting this with PBS-BSA. 
 The following morning the cells were rinsed with pre-warmed PBS-BSA 5 times with 1 
min incubations. Next the cells were incubated in a dark cupboard for 1hr at RT with 100µl 
of one of the following secondary antibodies: donkey anti-rabbit IgG (H+L) Alexa Fluor® 
488 (# A21203 Invitrogen) or donkey anti-mouse IgG (H+L) Alexa Fluor® 549 (#A21203 
Invitrogen) diluted at 1:200 and 1:2500, respectively in 0.05% PBS-BSA. After 30mins 
into the secondary antibody incubation period, slides were further incubated with an 
additional 100µl of Cyto-painter Phalloidin iFluor 488 Reagent (# ab176753; ABCAM ®) 
to stain the F-actin cytoskeleton. Phalloidin is a heptapeptide that binds to F-actin. It 
stabilizes the filaments thereby preventing depolymerisation of actin fibers. An additional 
negative control was to include the secondary antibody incubation step, but to exclude the 
primary antibody, substituting this with PBS-BSA. 
2.3.1.3 Nuclear staining  
Subsequent to the secondary antibody and F-actin staining, the cells were rinsed 5 times 
with pre-warmed PBS-BSA at 1min incubations. The cells were then incubated in a dark 
cupboard for a further 5mins with a 100µl solution of 4’, 6-diamidino-2-phenylindole 
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(DAPI) (#236276; Cell Biology Boehringer Mannheim, Germany) at RT. The cells were 
then rinsed 5 times at 1min incubations with PBS. Next, the coverslips were mounted onto 
glass slides with Fluorogel Mount (#17985-10, Electron Microscopy Sciences) and were 
left to dry in the dark for a few hours. These were then placed in a box and stored at 4  C, 
till viewing the next day on a Carl Zeiss LSM 780 Confocal Microscope (63 X 
Magnification). 
2.3.1.4 Z-sectioning and 3 dimensional reconstruction analysis  
The properties of the confocal laser scanning microscope allow for the optical sectioning in 
the Z- axis. The pinhole, a small, adjustable diaphram placed in front of the PMT (see 
Figure 2.2), eliminates unwanted light from out-of-focus areas. Capturing a series, or stack, 
of images focused at regularly placed intervals through the depth of an object of interest 
allows one to subsequently create renderings to visualise the entire sample in 3 dimensions 
(3D). Z-stacking of specimens was recorded using the Z-stack mode of the Carl Zeiss LSM 
780 Confocal microscope (63X Magnification) (Appendix D).  
2.4 Cell migration study 
To assess cell migration the scratch assay technique was used. Here cells are seeded onto a 
sterile glass coverslip and grown to confluence. A cell-free area referred to as a ―gap‖ was 
created by scoring through the cell monolayer with a sterile plastic pipette tip (Kramer et 
al., 2013). The gap closure by cell migration is then monitored by microscopy over a 
specific period of time. This assay can directly reflect the cell dynamics and cell contacts 
that are involved in cellular migration (Liang et al., 2007, Kramer et al., 2013). Thus the 
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time it takes for the gap to close is an indication of the migration potential of the cell line 
(Liang et al., 2007). 
2.4.1 Cell migration assay 
Approximately 50000 cells/ml (in appropriate culture media) were seeded onto heat 
sterilised glass coverslips contained in each well of a 6 well cell culture plate (SPL Life 
Sciences) and were allowed to reach 100% confluence. The coverslips were then rinsed 3 
times with PBS and 1ml of serum-free medium was then added, to facilitate 18-20 hours of 
serum starvation; subsequently the serum-free medium was removed and the wells were 
rinsed once with PBS. Next, the coverslip was scored or scratched through the confluent 
monolayer of cells with a sterile (200 µl) pipette tip to create a cell-free area. Following 
this, the coverslip was rinsed once with PBS to remove any cell remnants from the scored 
area. Thereafter 1 ml of complete medium containing either 20 µM DAPT, 20 µM DBZ, or 
20 µl DMSO (vehicle control) or 1 ml of complete drug-free medium (untreated control) 
was added to each well. The gap closure was monitored every 2 hours for 48 hours to 
analyse the cell migration distance over time, this with an inverted microscope (Olympus 
IX71), and viewed under a 4X objective. The images were captured with an Olympus 
CKX41 camera. The extent of migration of cells into the gap was calculated at three points 
(Appendix E.1); the quantification of the relative closure of the gap was undertaken and 
compared with that of the control by using ImageJ software; pixels were converted to µm 
to obtain the value pixels/µm (Appendix E.1).   
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2.5 Data analysis 
 Experiments were performed in biological triplicates. All average and standard deviation 
(SDV) values were calculated in Microsoft Excel 2010 and were exported to Graph Pad 
PrismPad Prism, version 5. To evaluate the statistical difference between normal growth CI 
values of all three cell lines, non-parametric ANOVA analysis, followed by the Kruskal 
Wallis test were performed. To assess the effect of GSI between MCF-7 and MDA-MB-
231 or MCF-7 and MDA-MB-436, an unpaired Student’s t-test was calculated with 95% 
confidence. Finally, to evaluate the effects of the different GSIs on a cell line, a paired 
Student’s t-test was calculated with 95% confidence. A p-value that was <0.05 was 
considered significant. 
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CHAPTER 3: RESULTS  
3.1 Determination of the activity of Notch and the effect of gamma 
secretase inhibition   
3.1.1 Notch signalling is active in breast cancer cells and NIC expression decreases 
post- inhibitor treatment 
To determine the activity of Notch signalling in human BC cells and the expression and 
localisation of NIC within the cells, indirect immunofluorescence was used. BC cells were 
stained with an anti-NIC antibody, the cleaved product of γ-secretase which represents the 
activity of the pathway (Figure 1.4). This (NIC) was then localised using a secondary 
antibody conjugated to a fluorescent Alexa Fluor dye. In order to control for non-specific 
antibody binding, negative controls were carried out, wherein either the primary or the 
secondary antibody was omitted and substituted with PBS. These controls effectively 
showed a lack of non-specific primary or secondary antibody binding (see Appendix D.1). 
Following serum starvation the cells were then treated with 20µM DAPT, 20µM DBZ, 
20µl DMSO (vehicle control) or complete drug-free (untreated) medium , respectively, for 
48hrs. The MCF-7 cell line demonstrated specific NIC (green) localisation, which 
appeared as discrete punctate areas on the nucleus (blue), being specifically associated 
with the nucleoli, the expression of which decreases when treated with each inhibitor 
(Figure 3.1-panel A- L arrows). In addition there is also some perinuclear staining that was 
observed. 
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In all the cell lines DAPT treatment results in a more drastic decrease of the NIC signal 
compared to DBZ and DMSO. The MDA-MB-436 cell lines show the same NIC-nucleoli 
localisation, but with a lower expression than in the MCF-7 drug treated cells (Figure 3.1-
panel I) and untreated cells. DAPT in these cells also causes a marked decrease in NIC 
expression compared to treatment with each of DBZ and DMSO (Figure 3.1 panel J-L).  
In the MDA-MB-231 cell line, NIC expression was raised, being concentrated both in a the 
perinuclear staining pattern  and also being dispersed over the nucleus, largely masking the 
nucleoli that are visible in the nuclei of the other two cell lines (Figure 3.1 panel E-F). The 
nucleoli following NIC localisation are only faintly visible post-GSI treatment; and 
furthermore, both GSI’s cause a dramatic decrease in nucleoli associated expression of 
NIC in the MDA-MB-231 cell line (Figure 3.1 panel G-H). 
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Figure 3.1. Notch signalling is active in breast cancer cells and its expression decreases post 
inhibitor treatment. Cells were treated with 20µM of either DAPT or DBZ. DMSO was used as a 
vehicle control. Each drug inhibits the pathway as the NIC signal represented by positively staining  
green nucleoli, decreases post-treatment. DAPT decreased the expression of NIC in MDA-MB-436 
(Panel I-L) and MCF-7 (Panel A-D) cell lines, respectively. Both DAPT and DBZ decrease the 
expression of NIC in MDA-MB231 (Panel E-H). [Cells were stained with  donkey anti-rabbit IgG 
(H+L) Alexa Fluo® 488 (# A21203 Invitrogen)  to detect NIC (green) and  DAPI  for the 
nucleus(blue); and visualised using a Carl Zeiss LSM 780 Confocal Microscope, 63X objective.]. 
Key: A-D= MCF-7; E-H= MDA-MB231; I-L=MDA-MB436 NIC= Notch Intracellular Component  
NU=Nucleus  
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3.2 Effect of Notch on breast cancer cells 
3.2.1 Oestrogen receptor positive cells grow more rapidly compared to TNBC cell lines 
Following on the evaluation of Notch activity, through NIC expression in the hormone 
insensitive and hormone responsive BC cell lines, it was of interest to determine the 
potential effects of the pathway on cell proliferation.  
Firstly, cell impedance assays using the xCelligence instrument (Roche) were used to 
evaluate the normal growth profiles of each cell line. The curves presented below (Figure 
3.2) represent 3-repeats for each cell line. The MCF-7 cell line (blue) has a cell index (CI) 
of 6.9836 at 74.5hrs, which is the highest among the three cell lines. The MDA-MB-
231(red) and MDA-MB-436 (green) cell lines have a CI of 1.9799 and 3.1712 respectively 
(Figure 3.2). The MCF-7 cells grow exponentially (log phase) for 20 hours before 
beginning to plateau. These cells grow significantly (p<0.001, ANOVA, Kruskal Wallis 
test) faster, compared to, the MDA-MB-231 and MDA-MB-436 cell lines, which grow 
exponentially for 22 hours, before they begin to plateau (Figure 3.2).   
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Figure 3.2 Normal cell growth profile of hormone receptor positive cell line (MCF-7) 
compared to hormone receptor negative positive cell line (MDA-MB-231 and MDA-MB-436). 
Cell impedance shows that MCF-7 (blue) has higher cell index compared to MDA-MB-231 (red) 
and MDA-MB-436 (green). The MCF-7 cell line has a significantly faster growth curve (p<0.001, 
ANOVA, Kruskal Wallis test)   compared to MDA-MB-231 and MDA-MB-436 cell lines. Error 
bars represent standard deviation of N=3. 
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3.2.2 Notch signal pathway inhibition decreases cell proliferation and viability in 
breast cancer cells 
To determine the effects of Notch signalling on cell proliferation and viability, GSI’s were 
used. Prior to drug treatment, each of the cell lines were serum starved (Appendix C.3) and 
then treated with 20µM DAPT, 20µM DBZ, and 20µl DMSO (vehicle control) or complete 
drug-free medium (media control), respectively. As an initial assessment of the 
pharmacological activity of the GSI’s on cell growth, the end-point TB cell viability assay 
was employed. This was then compared with the real-time measurements of cell viability 
measured with the xCelligence-RTCA instrument (Roche).  
3.2.2.1 Trypan blue assay cell viability 
The results of the TB assay show that cell viability decreases non-significantly with DBZ 
treatment in all cell lines, after 48hrs of treatment (Figure 3.3). Treatment with DAPT 
resulted in a 67% cell viability of the MDA-MB-231 cell line. The viability is less 
compared with the 87.68% and 96.67% of the MCF-7 and MDA-MB-436 cell lines, 
respectively.  
All three cell lines were sensitive to DBZ, with a 29% , 27.67% and 22.22% decrease in 
cell viability of MCF-7, MDA-MB-231 and MDA-MB-436 cell lines respectively (Figure 
3.3). Despite observing this trend of sensitivity, the effect of each treatment on each cell 
line was not statistically significant (p> 0.05, ANOVA, Kruskal Wallis test). Nevertheless 
a comparison between the DBZ and DAPT treatments shows that the effects of these drugs 
were significantly different (p<0.05, paired Student’s t-test) in the MDA-MB-231cells. 
However, their pharmacological effects were indifferent in both of the MCF-7 and MDA-
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MB-436 cell lines, respectively (p> 0.05, paired Student’s t-test). There is no significant 
difference between the DMSO vehicle control and Media control, indicating that DMSO 
does not have anti-proliferative effects on each cell line. 
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Figure 3.3 TB assay cell viability of breast cancer cells. TB assay following 48hrs of GSI 
treatment shows that DBZ decreased cell proliferation in MCF-7(blue), MDA-MB-231(red) and 
MDA-MB-436(green), cell lines although not significantly (p>0.05, paired Student’s t-test). The 
proliferation of the MDA-MB-231 cell lines was significantly affected by DAPT (p<0.05, paired 
Student’s t-test). Overall, GSI treatment did not cause a statistically significant decrease in cell 
viability (p> 0.05 ANOVA, Kruskal Wallis test) in all three cell lines. Error bars represent standard 
deviation of N=3. 
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3.2.2.2 xCelligence-RTCA cell proliferation and viability 
In assessing cell viability and cell proliferation using xCelligence, at the end of 48hrs of 
drug treatment the CI for the MCF-7 cell line was 1.7920 when treated with DAPT which 
was significantly less, compared to a CI of 2.6847 than when treated with DBZ (p < 0.05 
paired, Student’s t-test). In comparison, the proliferation and viability of the MDA-MB-
231 and MDA-MB-436 cell lines was significantly more decreased by DBZ, with CI’s of 
0.3704 and 0.4958 , respectively  (p< 0.05 paired Student’s t-test), when compared to the 
CI’s of 0.4360 and 0.67503,  after DAPT treatment. 
With a CI of 3.3671, 0.4800 and 0.8200 for MCF-7, MDA-MB-231 and MDA-MB-436, 
respectively, the vehicle control DMSO decreases cell viability and proliferation. 
However, this was not as significant as the recorded effects of GSI’s on each of the cell 
lines (Figure 3.4, 3.5 and 3.6). Overall the results show that decrease of both cell viability 
and proliferation following inhibition of Notch was statistically significant in the TNBC 
cell lines compared to the receptor positive cell line  (p<0.001, ANOVA, Kruskal Wallis 
test).  
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Figure 3.4 GSI treatment inhibits cell proliferation of MCF-7 breast cancer cell lines. DAPT 
(green) decreased the CI of the MCF-7cell line to 1.7920; this decrease was statistically significant 
compared to the decrease in CI of 2.684 produced by DBZ (purple) (p<0.001, paired Student’s t-
test). Overall  both of the GSI’s had a more significant effect on the cell proliferation and viability 
when compared to the CI’s of the media control (blue) and DMSO (red) vehicle control, which 
were 4.7388  and 3.3671, respectively (p< 0.001, non-parametric unpaired Student’s t-test). Error 
bars represent standard deviation of N=3. 
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Figure 3.5 GSI treatment inhibits cell proliferation of MDA-MB-231 breast cancer cell lines. 
DBZ (purple) decreased the CI of the MDA-MB-231 cell line to 0.3704; this decrease was 
statistically significant compared to the decrease in CI of 0.4360 produced by DAPT (p<0.001, 
paired, Student’s t-test). Overall both of the GSI’s had a more significant effect on the cell 
proliferation and viability when compared to the  CI’s of the media control (blue) and DMSO (red) 
vehicle control, these were 0.9860  and 0.4800, respectively (p< 0.001, non-parametric unpaired, 
Student’s t-test). Error bars represent standard deviation of N=3. 
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Figure 3.6 GSI treatment inhibits cell proliferation of MDA-MB-436 breast cancer cell line. 
DBZ (purple) decreased the CI of the MDA-MB-436 cell line to 0.4958; this decrease was 
statistically significant compared to the decrease in CI of 0.6750 produced by DAPT (green) 
(p<0.001, paired Student’s t-test). Overall  both of the GSI’s had a more significant effect on the 
cell proliferation and viability when compared to the CI’s of the media control (blue) and DMSO 
(red) vehicle control, which were 0.945 and 0.8200 respectively (p< 0.001, non-parametric 
unpaired Student’s t-test). Error bars represent standard deviation of N=3. 
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3.3 Effect on cell morphology and cell migration 
3.3.1 Notch inhibition decreases expression of E-cadherin in MCF-7 cells and alters cell 
morphology in MDA-MB-231 and MDA-MB-436 cell lines. 
3.3.1.1 The expression of E-cadherin in human breast cancer cells 
To evaluate the potential of Notch inhibition on a marker of cell adhesion and migration 
indirect immunofluorescence was used to detect the BC tumour invasion marker E-
cadherin (Figure 3.7 and 3.8) (Singhai et al., 2011). This was done to assess whether there 
is a change in the expression and localisation of E-cadherin in BC cells post drug-
treatment. The cell membranes were either permeabilized or not permeabilized, to assess 
intracellular localisation or cell surface localisation, respectively. To further assess the 
precise localisation of the markers of interest, Z-section sectioning and 3D surface 
projections of the cells were analysed. 
In the permeabilised cell group, E-cadherin is highly expressed in the MCF-7 cell line 
within the cytoplasm, the nucleus and the cell membrane (supplementary image in 
Appendix D.3). Its expression decreases when treated with GSI, whereby DBZ causes a 
greater decrease compared to DAPT treatment (Figure 3.7-a panel A-D; Figure 3.7-b panel 
A-D; Figure 3.8-c panel A-D and Figure 3.8-d panel A-D).  
The MDA-MB-231 cell line appeared not to express E-cadherin pre-treatment, indicating 
that it is a highly invasive cell line and that it has a high migration potential. Post GSI 
treatment, its expression was not up-regulated (Figure 3.7-a panel E-H; Figure 3.7-b panel 
E-H). Similarly the MDA-MB-436 cell line does not appear to express E-cadherin and 
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treatment with GSIs did not alter this status (Figure 3.7-a panel I-L; Figure 3.7-b panel I-
L). 
The non-permeabilised cell group shows a similar staining pattern for E-cadherin 
expression in all the cell lines, as recorded for the permeabilised breast cell group. The 
MDA-MB-231 and MDA-MB-436 cell lines lacked any E-cadherin expression at any 
intracellular location (Figure 3.8-a panel E-H; Figure 3.8-b panel E-H; Figure 3.8-a panel 
I-L; Figure 3.8-b panel I-L). 
3.3.1.2 The morphology of human breast cancer cells 
Next, to determine the effect of GSIs on the cytoskeleton, indirect immunofluorescence 
was used to visualize the F-actin cytoskeleton with fluorescently labelled phalloidin 
(Figure 3.7-a; Figure 3.7-b; Figure 3.8-a and Figure 3.8-b). Following drug treatment, the 
F-actin cytoskeleton of the MCF-7 cell line was apparently not adversely affected by the 
GSIs. Although the cells appear slightly detached from each other (Figure 3.7-a panel B, 
C), their shape remains the same, as in the untreated control (Figure 3.7-a panel A).  
In MDA-MB-231 cells DBZ caused a change in the distribution of F-actin, as it appears 
aggregated around the nucleus (Figure 3.7-a and 3.7-b panel; Figure 3.8-a and 3.8-b panel 
H) which results in a change in cell shape from a fibroblast shape (Figure 3.7-a panel E and 
Figure 3.8-a panel E) when untreated to a more round shape post-treatment. With DAPT 
treatment the F-actin cytoskeleton aggregates adjacent to the nucleus (Figure 3.7-a panel G 
and Figure 3.7-b panel G) however, this was not observed in the non-permeabilised cells 
(Figure 3.8-a panel G and Figure 3.8-b panel G). The cytoplasmic stress fibers are lost as 
well as a result of DBZ and DAPT treatment (Figure 3.7-a panel E-H). 
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The F-actin cytoskeleton in the MDA-MB-436 cells is aggregated adjacent to the nucleus 
(Figure 3.7-a panel I-L; Figure 3.7-b panel I-L; Figure 3.8-a panel I-L and Figure 3.8-b), 
this is not affected by drug treatment. There is also nuclear localisation of F-actin 
observed, in DBZ treated non-permeabilised cells (Figure 3.8-a panel J, L and Figure 3.8-b 
panel J, L).The cytoplasmic stress fibers of these cells decrease post-treatment and there is 
in an increase in filapodia in the DAPT (Figure 3.7-a panel K) treated cells. 
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Figure 3.7 a) Effects of Notch inhibition on the expression of E-cadherin and cell morphology 
in permeabilised cells Permeabilised E-cadherin (red) expression decreases with inhibitor 
treatment (panel A-D). DBZ causes a decrease in E-cadherin expression in MCF-7 cells (panel D) 
whereas, F-actin (green) is relatively unaffected by either inhibitor (panel C and D). MDA-MB-231 
cells lack E-cadherin signal post-treatment with DAPT/DBZ (panel E-H). Furthermore, the 
distribution of F-actin within these cells is altered post-treatment (panel G and H), indicating a 
change in cell morphology. F-actin appears punctate in MDA-MB-436 (panel I-L) and MDA-MB-
231 (panel G).  
Key: NU= nucleus; E-cad=E-cadherin; CJ= Cell Junction; A-F= MCF-7; E-H=MDA-MB231; 
I-L=MDA-MB436 
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Figure 3.7 b) 3D projections, generated from Z-sectioning; Zeiss LSM 780 permeabilised 
cells. The YZ3 dimensional projection images of the cell lines seen which are represented in figure 
3.7-a. Here membrane staining of E-cadherin in the MCF-7 cell line is clearly visible (panel A-D) 
and there is aggregation of F-actin adjacent to the nucleus visible in the MDA-MB-231 (panel E-H) 
and MDA-MB436 cell lines (panel I-L). 
Key: NU= nucleus; E-cad=E-cadherin; CJ= Cell Junction; A-F= MCF-7; E-H=MDA-MB231; I-
L=MDA-MB436  
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Figure 3.8 a) Effects of Notch inhibition on the expression of E-cadherin and cell 
morphology in non-permeabilised cells. Non-Permeabilised E-cadherin (red) expression 
decreases with inhibitor treatment (panel A-D). DBZ causes a decrease in E-cadherin 
expression in MCF-7 cells (panel D) whereas, F-actin (green) is relatively unaffected by 
either inhibitor (panel A-D). MDA-MB-231 cells lack E-cadherin signal post-treatment 
with DAPT/DBZ (panel E-H). Furthermore, the distribution of F-actin within these cells is 
altered post-treatment, indicating a change in cell morphology. F-actin appears punctate in MDA-
MB-436 (panel I-L) and MDA-MB-231 (panel E, F). 
Key: NU= nucleus; E-cad=E-cadherin; CJ= Cell Junction; A-F= MCF-7; E-H=MDA-MB231; I-
L=MDA-MB436 
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Figure 3.8 b) 3D projection, generated from Z-sectioning; Zeiss LSM 780 non-permebilised 
The YZ 3 dimensional projection images of the cell lines seen which are represented in Figure 3.8-
c.  Here perinuclear staining of E-cadherin in MCF-7 cells (panel A-D) is clearly visible. 
Perinuclear and nuclear actin is visible in the MDA-MB-436 cell line (panel I-L).  
Key: NU= nucleus; E-cad=E-cadherin; CJ= Cell Junction; A-F= MCF-7; E-H=MDA-MB231; I-
L=MDA-MB436 
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3.3.2 Notch inhibition does not affect cell migration in  BC cell lines. 
 A scratch/migration assay was used to evaluate the effects of Notch signal pathway 
inhibition on cell migration. The distance the cells moved was recorded every 2hrs. This 
data is represented below by images of a scratch/migration assay and a plot of cell 
migration (gap closure) over time, for each respective treatment. 
After 48 hours of treatment with GSI, cell migration of the MCF-7 hormone sensitive cell 
line is not significantly different from either the untreated or the vehicle control (Figure 
3.9). Similarly the migration of MDA-MB-231 (Figure 3.10) and MDA-MB-436 (Figure 
3.11) cell lines is not significantly different, when compared to their respective vehicle and 
untreated controls.  
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Figure 3.9.a) Notch inhibition does not affect cell migration in MCF-7 cell line.  Scratch assay 
of MCF-7, gap closure was not significantly affected by the DMSO vehicle control and GSI 
treatment at 48hrs. The white arrow indicates the cell free area that was measured over time. The 
gap closure is represented in plots below. (4X magnification)  
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Figure 3.9 b) A plot representing the gap closure in Notch inhibited MCF7 cells. Gap closure 
was not significantly affected by either GSI treatment at 48hrs (p>0.05, paired Student’s t-test) and 
was not significantly different from the controls (p>0.05, ANOVA, Kruskal Wallis test). Error Bars 
represent standard deviation of N=3 
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Figure 3.10.a) Notch inhibition does not affect cell migration in MDA-MB-231 cell line. 
Scratch assay of MDA-MB-231, gap closure appears to have been inhibited by the DMO vehicle 
control and DAPT at 48hrs. Treatment with DBZ appears to have little effect on the cell line. The 
white arrow indicates the cell free area that was measured over time. The gap closure is represented 
in plots below. (4X magnification)  
 
79 
 
 
Figure 3.10 b) A plot representing the gap closure in Notch inhibited MDA-MB-231 cells.Gap 
closure was not significantly affected by either GSI treatment (p>0.05, paired, Student’s t-test) and 
was not significantly different from the controls (p>0.05, ANOVA, Kruskal Wallis test) at 48hrs. 
Error Bars represent standard deviation of N=3 
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Figure 3.11.a) Notch inhibition does not affect cell migration in MDA-MB-436 cell line.  
Scratch assay of MDA-MB-436 cells. Gap closure was not significantly affected by the DMSO 
vehicle control and GSI treatment at 48hrs. The white arrow indicates the cell free area that was 
measured over time. The gap closure is represented in plots below. (4X magnification)  
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Figure 3.11 b) A plot representing the gap closure in Notch inhibited MDA-MB-436 cells. Gap 
closure was not significantly affected by either GSI treatment (p>0.05, paired, Student’s t-test) and 
was not significantly different from the controls (p>0.05, ANOVA, Kruskal Wallis test). Error Bars 
represent standard deviation of N=3 
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CHAPTER 4: DISCUSSION  
It has been reported by Rizzo and colleagues that, the Notch signalling pathway is 
deregulated in BC and that it is activated in the absence of oestrogen (Rizzo et al., 2009).  . 
However to- date studies that confirm or challenge this have been few and far between. 
Moreover, studies that explore the relationship between Notch signalling and cell 
migration are sparse. In general research on the functional role of the Notch signalling 
pathway in TNBC is limited. The pertinent findings relating to Notch signalling in TNBC 
are discussed below. 
4.1 Notch expression and activity  
 The subcellular localisation of NIC may be a morphological illustration of the functional 
activity of notch in the cell (Speiser et al., 2013). NIC is released into the cytoplasm once it 
has been cleaved by γ-secretase. Whilst it is in the cytoplasm, NIC is inactive and thus the 
signal has yet to exert its effects on gene expression. However, once translocated to the 
nucleus subsequent binding to DNA binding factors then allows for Notch target gene 
activation. Therefore accumulation of NIC in the cytoplasm indicates an inactive Notch 
signal, whilst an accumulation of NIC in the nucleus represents the active form. 
When comparing the expression and localisation of NIC1 in hormone receptor positive cell 
lines to that of hormone insensitive cells, prior to γ-secretase inhibition, there was a 
similarity between the localisation of NIC1 in  both the MCF-7 and MDA-MB-436 cell 
lines; as this factor is present within the nucleus and it is  specifically associated with the 
nucleoli (Figure 3.1). This may be a good indication of the formation of the transcriptional 
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complex together with the DNA binding factors. While NIC1 was localised to the nucleoli 
of both cell lines, it differed in expression intensity; the MCF-7 cell line displayed more 
densely stained nucleoli compared to the MDA-MB-436 cell line, suggesting that Notch is 
more active in hormone receptor positive cells and less active in the hormone insensitive 
cells.  
The localisation and expression of NIC1 in the MDA-MB-231 cell line was quite different 
to the above-mentioned cell lines; in these, NIC1 was both concentrated in a perinuclear 
aggregation on one side of the nucleus, suggestive of a Golgi/endoplasmic reticulum 
association, and was also densely scattered over the nuclear membrane, effectively 
masking the nucleoli. The observation suggests that the pathway is hyperactive in those 
cells.  
Interestingly, though both the MB-MDA-231 and the MDA-MB-436 cell lines are TNBC 
models (Chavez et al., 2010), they express NIC differently. This may be seen as supporting 
evidence that there may indeed be subtypes of TNBC; this however is still quite 
controversial. It may also indicate that Notch activity is different within each subtype. This 
could indicate that oestrogen may not be an inhibitor of Notch, but rather that there may be 
crosstalk between Notch and other pathways that influence its activity. One such candidate 
may be the Wnt pathway; and, the MDA-MB-231 cell line possesses the WNT7B 
oncogene that is part of a large family of genes that regulate the WNT pathway (Huguet et 
al., 1994). Moreover, the deregulation of WNT is associated with BC, and it has been 
proposed that is involved in crosstalk with Notch signalling (Guo et al., 2011, Ayyanan et 
al., 2006, Yamaguchi et al., 2014, Visvader, 2009).   
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It is suggested here that the presence of the WNT oncogene in the MDA-MB-231 cell lines 
may be a factor influencing the up-regulation of Notch. In contrast the MDA-MB-436 cell 
line does not possess this gene, but Notch is down-regulated in these cells, which may 
indicate that in this instance a lack of oestrogen, may be causing deregulation in Notch 
activity in these cells. However, the MDA-MB-436 data obtained in the present study 
challenges the hypothesis that a lack of oestrogen increases Notch activity proposed by 
Rizzo et. al (2009) (Rizzo et al., 2009)  , who based this notion on the observed increase in 
Notch activity when MCF-7 cell lines were deprived of oestrogen, or when oestrogen is 
antagonized by selective ER modulators. In contrast, however the findings observed here 
from the MDA-MB-231 cell lines agree with their data in experimentally oestrogen 
deprived MCF-7 cells, where NOTCH-1 could be detected in both the cytoplasm and 
nucleus. To date there is no report in the literature referring to the distribution of NIC1 in 
MDA-MB-436 cell lines (Bolos et al., 2007).  
It is important to note here that the distribution of NIC1 alone is evaluated. Neither the 
distribution of NOTCH-2 intracellular component, NOTCH-3 intracellular component nor 
NOTCH-4 intracellular components were assessed. The expression and localisation of each 
of these could be remarkably different in each of the cell lines, since BC cells have been 
reported to co-express Notch receptors .  
4.2 The cellular growth, proliferation and viability of human breast 
cancer cells 
As recorded here, the hormone and growth receptor positive cells grow significantly faster 
than their receptor negative counterparts. This is somewhat expected as hormones and 
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growth factors are known to promote growth and proliferation of breast cells in vivo 
(Tarulli et al., 2014, Yarden, 2001, Sibilia et al., 2007). Although receptor positive BC 
grows much faster than TNBC, the latter is reportedly a more aggressive cancer (Dent et 
al., 2007). Therefore it is apparent that there are factors other than the presence of key 
breast cell receptors that are perpetuating TNBC tumours.  
From this it was hypothesised that deregulated Notch signalling may be a key factor in 
TNBC cell proliferation and the cell lines were thus treated with GSIs. Notably the TNBC 
cell lines were more sensitive to GSI treatment when compared with receptor positive cell 
lines. These data corroborate the results presented by Lee  et.al (2008) who found that GSI 
treatment of the MCF-7 and MDA-MB-231 cell lines decreased cell proliferation, to a 
greater effect in the MDA-MB-231 cell line (Lee et al., 2008a) . Also in the same study 
they found that GSI treatment abolished colony formation of MDA-MB-231 cells on soft 
agar, at the magnitude of three orders more than the MCF-7 cell line. In another study by 
Rizzo et .al (2009) GSI treatment of MDA-MB-231cells had strong anti-proliferative 
effects and when combined with Tamoxifen, GSI caused significant growth inhibitory 
effects (Rizzo et al., 2009). Additionally the combination of the GSI, PF-03084014 with 
docetaxel resulted in a decrease in tumour size and a reversal of chemo-resistance in 
TNBC xenograft models (Zhang et al., 2013). A preclinical study on breast tumours from 
30 patients with advanced BC of an unspecified subtype showed that a combination of the 
GSI, MK-0725 and docetaxel reduced the numbers of BC CSCs (Schott et al., 2013). 
Currently, there are three on going GSI/Notch pathway based clinical studies, two of which 
are specifically on TNBC (www.clinicaltrials.gov). One study is investigating the effects 
and the best dose of the GSI inhibitor, R04929097 when combined with paclitaxel and 
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carboplatin in patients with stage II and stage III TNBC (www.clinicaltrials.gov). The 
other investigates how well the same inhibitor will fair in treating patients with metastatic 
or recurrent TNBC. Overall, the findings reported on here concur with the literature having 
shown that GSI is effective in reducing TNBC cell proliferation and viability  
4.2.1 Classical end-point assay versus real-time cell analysis assay 
The TB classical end-point assay revealed that the GSIs do not affect cell viability of the  
MCF-7 and MDA-MB-436 cell lines, while the cell viability of MDA-MB-231 cell lines 
was significantly affected. These results differ from those produced by the RTCA system; 
this assay reveals that all cell lines are significantly affected by the GSI, demonstrating the 
sensitivity of evaluating cellular responses in real time. As well because it monitors cell 
behavior over time it is able to detect both cell viability and cell proliferation.  
4.3 Notch and cell migration and morphology 
In order to investigate the effect of inhibiting Notch on cell migration, the expression of the 
invasion and metastasis suppressor protein E-cadherin (Baranwal and Alahari, 2009) was 
assessed. Its normal physiologic process includes tissue morphology and epithelial-to-
mesenchymal transition (EMT), wherein cells lose their epithelial characteristics and 
acquire mesenchymal features (Abdulla et al., 2013). Since the activation of invasion and 
metastasis are a particular hallmark of cancer, E-cadherin expression is thus considered a 
good marker for BC malignancy (Hanahan and Weinberg, 2011).  
The receptor positive BC cells displayed a greater E-cadherin expression, which decreases 
when cells are treated with GSIs. The TNBC cell lines did not exhibit E-cadherin 
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expression and upon treatment with GSI it is not up-regulated in TNBC cells. The data 
observed here corroborate Chen et al. (2010) who report that an overexpression of NIC1 
inhibits E-cadherin, in MDA-MB-231 because prior experiments show that MDA-MB-231 
cell line overexpress NIC1 (Figure 3.1) (Chen et al., 2010)  . However, in contrast, when 
tumour xenografts from MDA-MB-231 cell lines were treated with GSI, 
immunohistochemical evaluation demonstrated an increase in E-cadherin expression, due 
to the GSI preventing its proteolysis (Leong et al., 2007).  
While in the present study it may then be hypothesised that a decrease in Notch could 
result in E-cadherin up-regulation, this however was not apparent in the MDA-MB-436 
cell line; instead E-cadherin expression was not detected. This suggests that possibly in 
some types of TNBC cell lines Notch and E-cadherin expression are independent or 
dependant on each other. This is a further example of the different behaviours of TNBC 
cell types and also provides evidence that the deregulation of the signal is different in 
TNBC tumours. 
Furthermore it is shown here that GSI treatment causes a disruption in the F-actin 
cytoskeleton in the TNBC cell lines, with DBZ affecting the F-actin cytoskeleton of the 
MDA-MB-231 cell line more so than DAPT treatment. This may be an indication that 
Notch deregulation may have adverse effects on the integrity of the F-actin cytoskeleton. 
Disruption of the cytoskeleton could disturb proper cellular function, such as cell motility 
and cell signalling. This in turn may possibly affect the ability of the cells to migrate as 
well as their ability to effectively communicate with neighbouring cells. As the cellular 
junctions are disturbed it’s most likely that activation of the Notch signal is aberrant. From 
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the literature it still unclear as to what effect Notch inhibition has on the F-actin 
cytoskeleton.  
The migration/scratch assay showed that pre-GSI treatment, MCF-7 cells had a far greater 
gap closure after 48hrs, when compared to TNBC cell lines, which showed less migration, 
especially the MDA-MB-436 cells. Post-treatment, the results were similar, wherein MCF-
7 cell migration was greater after 48hrs, compared to cell migration of the TNBC’s. Within 
each cell line regardless of treatment, however, the difference in cell migration was not 
statistically significant. A possible explanation for this result is that migration was studied 
under normoxic cell culture conditions. Other studies however have concluded that 
hypoxia activates Notch signal induced migration (Chen et al., 2010). The data obtained 
here also contradicts another study which reported that Notch inhibition of MDA-MB-231 
cells by DAPT and R04929097 GSIs increases E-cadherin expression together with a 
reduction in their invasive capacity (Bolos et al., 2013). It has been reported that 
knockdown of Notch-1 exhibited limited wound closure activity even after 48hrs (Zhao et 
al., 2014). 
4.4 Conclusion 
The data presented here show that Notch activity is more stable in hormone receptor 
positive MCF-7 cell line compared to TNBC cell lines. Moreover, while GSIs are effective 
in decreasing the cell proliferation of both subtypes of BC, TNBC were however the most 
sensitive to them.  
Sensitivity to ER status does not seem to be a strict regulator of Notch activity as each 
TNBC cell model seemed to express Notch in a different manner. Although not statistically 
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significant, cell migration did decrease with Notch inhibition and further work is required 
to reach a definitive conclusion relating to Notch and migration. 
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CHAPTER 5: PERSPECTIVES AND FUTURE WORK 
Although we demonstrate here that the Notch signal may be dysfunctional in TNBC, the 
effects of neither NOTCH-1 upregulation nor NOTCH- receptor knockdown were 
assessed, as this was beyond the scope of the study. In particular the modulation of the 
NOTCH-1 gene will allow for the testing of the hypothesis that NOTCH-1 expression 
regulates for cell proliferation in TNBCs. Moreover, it may be important to replicate the 
present studies under hypoxic conditions, since it is reported in the literature that this 
activates Notch, causing an increased BC cell migration. Such an approach may be of some 
consequence since hypoxia rather than normoxia may be indicative of the in vivo tumour 
environment.  
 
5.1 Proposed approach for future work   
To further elucidate the role of the Notch pathway, it is proposed that further in vitro 
studies be carried out with MCF-7 and T47D cell line as the receptor positive BC 
representative cell line and MDA-MB-231 and MDA-MB-436 cell lines as the TNBC 
representative cell line. To assess the effects of Notch-1 down-regulation on cell 
proliferation and migration, siRNA knockdown of the NOTCH-1 gene should be carried 
out and monitored using the RTCA system. Moreover, an effective means to determine 
more precisely the effects of NOTCH-1 activity would be an inducible system of NOTCH-
1 expression. In association with this, it may be important to evaluate further changes in 
cell adhesion proteins, such as integrins and other EMT markers, for example Vimentin 
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Each experiment would be performed under both normoxic and hypoxic conditions to 
further understand the relationship between Notch and BC cell migration. Below is a 
diagram of the proposed scheme for future work (Figure 5.1). In summary fine control of 
Notch gene expression will provide for a better understanding of Notch expression in 
breast cancer. 
 
 
 
 
 
Figure 5.1. Diagram representing the methodology for future work. BC cell lines will 
maintained in appropriate media.Notch-1 expression induced using a NIC1 inducible clone. 
Knockdown of NOTCH-1 may be done using siRNA and the effects thereafter, can be evaluated 
using xCelligence, Western-blot and confocal immunofluorescence.  
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Appendix A: Protocols 
A.1 Preparation of solutions and reagents 
A.1.1 1X Phosphate Buffered Solution (PBS)  
1 PBS tablet (# P4417-100TAB; Sigma Life Sciences, USA) was dissolved in 200ml of 
distilled water  to make a 1X PBS solution and was sterilised  by autoclaving it. 
A.1.2 Blocking buffer 
 0.5% of bovine serum albumin (BSA) (# CAS9048-46-8, Santa Cruz Biotechnology, 
USA) was mixed with PBS (PBS/BSA). 
A.1.3 Fixing Solution/Buffer 
3% of formaldehyde (#104003, Merk, SA) in 1X PBS solution 
A.1.4 Permeabilisation solution/Buffer 
0.25% (v/v) of t-Octylphenoxypoly ethoxyethanol (TritonX-100) (#T-9289; Sigma Life 
Sciences, USA) was dissolved in PBS/BSA. 
A.1.5 F-actin cytoskeleton staining solution  
To prepare 1X Phalloidin conjugate working solution. Add 1µl of 1000X Cyto-painter 
Phalloidin iFluor 488 Reagent (# ab176753; ABCAM ®, USA) conjugate DMSO solutions 
into 1ml PBS/BSA. 
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A.1.6 Nuclear stain  
4’,6-diamidino-2-phenylindole (DAPI) (#236276 ; Cell Biology Boehringer Mannheim , 
Germany) was received in a  10mg crystalized form and was dissolved in N,N-
Dimethylformamide (DMF) to make up a stock solution of 5mg/ml. 
The working solution of DAPI was prepared by re-suspending 1µl of stock solution in 
10ml PBS. It was aliqouted in 2ml Eppendorf tubes and kept frozen at -20 C  until use. 
 
A.1.7 Cell culture media  
Table A1:  Media preparation for MCF-7, MDA-MB-231 and MDA-MB-436 cell lines. 
 
Cell 
line 
Growth medium 
MCF-7  DMEM-F12 (#BE12-719F, Biowhittaker
® 
Lonza,USA)  was supplemented with 
5ml FBS (#SV30160.03, HYCLONE®,USA)  and 100µl of 100µg/ml pen/strep 
solution (#17-602E, Biowhittaker® Lonza,USA) 
MDA-
MB-
231 
DMEM-F12(#BE12-719F, Biowhittaker® Lonza,USA )  was supplemented 
with 5ml FBS(#SV30160.03, HYCLONE® ,USA)   and 100µl of 100µg/ml 
pen/strep solution(#17-602E, Biowhittaker® Lonza,USA) 
MDA-
MB-
436 
Leibovitz (#BE12-700F, Biowhittaker® Lonza,USA) media was supplemented 
with 50µl of human insulin (#1927,Sigma Life Sciences, USA), 5ml 
FBS(#SV30160.03, HYCLONE®, USA)   , 100µg/ml pen/strep solution (#17-
602E, Biowhittaker® Lonza,USA) and 40µl of L-glutamine (#G7513, 
Sigma,USA) 
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A.1.8 Freezing media and thawing media 
Freezing media contained 15% Dimethyl Sulfoxide (#D2650; Sigma Life sciences, USA) 
(DMSO) and 20% FBS in media appropriate for each cell line. DMSO is used as a cryo-
preserving agent. 
Thawing media contained 20% FBS in media appropriate for each cell line. The additional 
FBS is added to aid cell recovery from DMSO as well as cell adherence. 
A.2 Pharmacological inhibitor concentration calculations 
A.2.1 DAPT stock solution 
N-(N-3, 5-Diflurophenacetyl-L-alanyl))-S-phenyl glycine t-Butyl Ester (DAPT) (#D5942-
5mg; Sigma Life Sciences,USA) is in a lyophilized form and must be dissolved in  DMSO 
to make a 10mM stock solution. The concentration was calculated: 
Mass = Concentration x Volume x Molecular Weight 
5mg = (10mM) (x) (432.46) 
X = 1.1562  
Therefore the volume of DMSO required making a 10mM stock solution from 5mg DAPT 
powder is 1.1562ml. 
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A.2.2 DBZ stock solution 
N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-
methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide (DBZ) (#CAS209984-56-5,Tocris 
Biosciences, Bristol UK) is a lyophilized and must be dissolved in  DMSO to make a 
10mM stock solution. The concentration was calculated as:  
Mass = Concentration x Volume x Molecular Weight 
10mg = (10mM) (x) (467.98) 
X = 2.1368ml  
Therefore the volume of DMSO required making a 10mM stock solution from 10mg DBZ 
powder is 2.1368ml. 
DAPT and DBZ working solution calculation was given by (stock solution calculation in 
appendices 1.3.1 and 1.3.2): 
C1V1=C2V2 
(10mM)(x)= (10µM) (100µl) 
x = 0.1µl 
C1V1=C2V2 
(10mM)(x)= (10µM) (1ml) 
x = 1µl 
Therefore 0.1µl of DAPT/DBZ in 99µl of cell culture media makes 10µM and 20µM 
solution would mean adding 0.2µl of DAPT/DBZ in 98µl in cell culture media and 1µl of 
DAPT/DBZ in 999µl of cell culture media makes 10µM and 2µl in 998µl of cell culture 
media makes 20µM. 
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Appendix B: Cell culture maintenance and ethics 
B.1 Cell sub-culture  
Cells were passaged once they had reached 90% confluence. The cell culture medium was 
poured out of the flasks and thereafter the cells rinsed thrice with 2ml of 1X PBS, then 1ml 
of trypsin/EDTA (#BE17-161E, Biowhittaker ® Lonza, USA) was poured onto the cells 
and was left to incubate for 3mins at 37  C in 5  CO2  ( ThermoForm series ll water 
jacketed CO2 Incubator [HEPA FILTER]). After 3mins, 1ml of culture media that was 
appropriate to the cell line being sub-cultured was poured onto the cells to deactivate 
trypsin/EDTA. The cells were triturated gently and 2ml of the cell suspension was 
transferred into a 15ml tube (SPL Lifesciences, Korea) and centrifuged at 1000 rpm for 
3mins. The supernatant was discarded and cells were re-suspended in 1ml of media 
(appropriate for the cell line being that was being sub-cultured). The cell suspension was 
split in a 1:2 ratio and then added into 4ml of pre-warmed cell culture media in a culture 
flask. 
B.2 Cell Freezing  
Sub-culturing procedures were followed until the centrifugation step. The supernatant was 
discarded and cells were re-suspended in 1ml of cold freezing media. The cell suspension 
was diluted in a 1:5 ratio to obtain an ideal freezing density , 1ml of the suspension was 
aliquoted into cryo-vials (Greiner Bio-one , Germany) and transferred to a polystyrene 
tube rack to freeze slowly overnight at -70  C  the following day the cryo-vials were 
transferred to a -80  C freezer. 
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B.3 Cell thawing  
Prior to thawing, 1ml of thawing medium was aliquoted into a 15ml tube and another 4ml 
was aliquoted into a cell culture flask (SPL-Lifesciences, Korea) and placed in the 
incubator to warm up. The cryo-vials were removed from the -80οC freezer and sprayed 
down with 70% ethanol.  The cells were thawed by rubbing the vials in-between gloved 
hands- this was done to avoid possible contamination from the water bath. Once cells had 
thawed they were immediately transferred into the 1ml of pre-warmed medium. The 
suspension of cells was centrifuged at 1000 rpm for 3mins to wash out the DMSO from the 
cells. The supernatant was discarded and the cells were re-suspended in 1ml of warm 
thawing media and suspension was transferred into 4ml of pre-warmed thawing media.  
B.4 Cell counting 
 Once the cells had been re-suspended in media after centrifugation (from 1.2.2 or 1.2.3), 
the cell suspension was mixed with Trypan Blue dye solution (#17-942E; Biowhitattaker® 
Lonza,USA) in a 1:1 ratio and 10µl of that mixture was pipetted into a disposable cell 
counting slide (#1450011; Bio-rad,USA ) which was then inserted into a TC10 automated 
cell counter (Bio-rad,USA) or was counted manually with a disposable haemocytomer 
fastread counting slide (#BVS100; Immune systems, UK). The heamocytomer was viewed 
under an inverted phase contrast microscope (Carl Zeiss 426126 Axiovert 25) and 2 grids 
were counted. Concentration (count/ml) was calculated by: 
Counts/ml = (total counts/number of complete 4x4 grids counts) x104 x sample dilution  
Cell seeding densities were adjusted to the optimal cell concentration by calculating: 
C1V1=C2V2    
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B.5 Ethic waiver  
Attached below is the ethics approval letter from the Human research committee (medical). 
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APPENDIX C: Cell growth, proliferation and viability raw Data 
C.1 Normal growth profile cell number optimisation   
Table C.1: Dilution series for cell seeding densities for growth signature optimization. 
CELL LINES MCF-7 MDA-MB-231 MDA-MB-436 
SERIES 1 10000 10000 20000 
SERIES 2 5000 5000 10000 
SERIES 3 2500 2500 5000 
SERIES 4 1250 1250 2500 
SERIES 5   1250 
 
 
Figure C.1 Optimising cell seeding density of MCF-7 cell line. Effect of cell density on CI, Cell 
growth signature for MCF-7 cell line over a period of 77 hours, cells were seeded at 10000 cell  
(red) ; 5000 cells(green)  and  2500cells (blue). The Error bars represent the CI at ± standard 
deviation. Optimisation of seeding density was repeated in triplicate. 
122 
 
 
Figure C.2 Optimising cell seeding density of MDA-MB-231cell line.  Effect of cell density on 
CI, Cell growth signature for MDA-MB-231 cell line over a period of 150.0 hours, cells were 
seeded at 10000 cell  (red) ; 5000 cells(green)  and  2500cells (blue).  The Error bars represent the 
CI at ± standard deviation. Optimisation of seeding density was repeated in triplicate 
 
 
 
 
 
Figure C.3 Optimising cell seeding density of MDA-MB-436 cell line.  Effect of cell 
density on CI, Cell growth signature for MDA-MB-436 cell line over a period of 77 hours, 
cells were seeded at 10000 cell  (red) ; 5000 cells(green)  and  2500cells (blue).  The Error 
bars represent the CI at ± standard deviation. Optimisation of seeding density was repeated in 
triplicate. 
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C.2 Trypan blue assay and cell viability drug concentration optimisation 
C.2.2 Trypan Blue viability assay 
Table C.2: Average percentage values of MCF-7 cell viability. 
 
Concentration 10µM 20µM 30µM 40µM 50µM 
DBZ 89.6667 29 44.4433 73 87.6667 
DAPT 95.8333 87.68 81 55.6667 100 
DMSO 98.8333 100 77.7767 66.64 67.7733 
MEDIA 99 100 95.3333 94.4433 100 
 
 
Table C.3: Standard deviation values of MCF-7 cell viability. 
 
Concentration 10µM 20µM 30µM 40µM 50µM 
DBZ 3.2146 25.1197 41.942 12.1244 21.362 
DAPT 3.7072 1.12089 5.2915 5.1316 0 
DMSO 2.0207 0 4.80933 0.03464 1.92835 
MEDIA 0 0 8.0829 9.62443 0 
 
 
Table C.4: Average percentage values of MDA-MB-231 viability. 
 
Concentration 10µM 20µM 30µM 40µM 50µM 
DBZ 88.5 27.6666667 41.6667 46.6667 86.9867 
DAPT 89 67.0533333 87 9.66667 88.8867 
DMSO 94.6667 99.1666667 38  100 
MEDIA 100 100 96  59.6667 
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Table C.5: Standard deviation values of MDA-MB-231 cell viability. 
 
Concentration 10µM 20µM 30µM 40µM 50µM 
DBZ 10.037 9.2376 14.4338 50.3322 4.95 
DAPT 9.777 4.7622 11.2694 16.7432 19.2489 
DMSO 9.2376 1.44338 33.6452  0 
MEDIA 0 0 6.9282  52.7289 
 
 
Table C.6: Average percentage values of MDA-MB-436 cell viability. 
 
Concentration 10µM 20µM 30µM 40µM 50µM 
DBZ 89.0833 22.22 87.7767 29 100 
DAPT 92.4167 96.6666667 97.2 91.6667 100 
DMSO 96.75 95.0666667 100 100 100 
MEDIA 97 100 87.6667 33.3333 100 
 
 
 
Table C.7: Standard deviation values of MDA-MB-436 cell viability. 
 
Concentration 10µM 20µM 30µM 40µM 50µM 
DBZ 3.3292 38.4862 10.7159 34.3948 0 
DAPT 1.59478 3.05505 4.84974 14.4338 0 
DMSO 2.20681 6.65307 0 0 0 
MEDIA 0 0 2.88675 57.735 0 
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C.2.3 Cell proliferation raw data 
 
Figure C.4 Real-time cell proliferation and viability of the MCF-7 cell line over 88 hours. 
Cells were serum starved for 22 hours prior to drug treatment.  
 
 
 
 
 
 
 
 
Figure C.5 Real-time cell proliferation and viability of the MD-MB-231 cell line over 
200 hours. Cells were serum starved for 22 hours prior to drug treatment.  
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Figure C.6 Real-time cell proliferation and viability of the MDA-MB-231 cell line over 119 
hours. Cells were serum starved for 22 hours prior to drug treatment.  
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Appendix D: Indirect immunofluorescence  
Negative controls of immunofluorescence 
D.1 Negative controls for the Notch-1 intracellular component signalling 
expression and localisation 
Negative controls included cells incubated with the primary antibody but excluded the 
secondary antibody and those incubated with secondary antibody but exclude the primary 
antibody. Images to represent these may be viewed below (Figure. D.1-3):  
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Figure D.1. A)  Negative controls of MCF-7 cell line in confocal microscopy. Where the 
primary antibody was excluded it was marked ―no primary‖ and when a secondary antibody was 
excluded it was marked ―no secondary‖. The top panel shows the controls for the untreated cells 
and the bottom panel shows controls for DMSO vehicle control. 
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Figure D.1.B) Negative controls of MCF-7 cell line in confocal microscopy. Where the primary 
antibody was excluded it was marked ―no primary‖ and when a secondary antibody was excluded it 
was marked ―no secondary‖. The top panel shows the controls for the DAPT treated cells and the 
bottom panel shows controls for DBZ treated cells. 
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Figure D.2. A) Negative controls of MDA-MB-231cell line in confocal microscopy. Where the 
primary antibody was excluded it was marked ―no primary‖ and when a secondary antibody was 
excluded it was marked ―no secondary‖. The top panel shows the controls for the untreated cells 
and the bottom panel shows controls for DMSO vehicle control. 
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Figure D.2 B) Negative controls of MDA-MB-231cell line in confocal microscopy. Where the 
primary antibody was excluded it was marked ―no primary‖ and when a secondary antibody was 
excluded it was marked ―no secondary‖. The top panel shows the controls for the DAPT treated 
cells and the bottom panel shows controls for DBZ treated cells.  
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Figure D.3. A)  Negative controls of MDA-MB-436 cell line in confocal microscopy. Where the 
primary antibody was excluded it was marked ―no primary‖ and when a secondary antibody was 
excluded it was marked ―no secondary‖. The top panel shows the controls for the untreated cells 
and the bottom panel shows controls for DMSO vehicle control. 
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Figure D.3. B)  Negative controls of MDA-MB-436 cell line in confocal microscopy. Where the 
primary antibody was excluded it was marked ―no primary‖ and when a secondary antibody was 
excluded it was marked ―no secondary‖. The top panel shows the controls for the DAPT treated 
cells and the bottom panel shows controls for DBZ treated cells. 
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D.2 Negative controls for the expression and localisation of E-cadherin 
 
 
 
Figure D.4. A) E-cadherin negative controls of MCF-7cell line in confocal microscopy. Where 
the primary antibody was excluded it was marked ―no primary‖ and when a secondary antibody 
was excluded it was marked ―no secondary‖. The top panel shows the controls for the untreated 
cells and the bottom panel shows controls for DMSO vehicle control. 
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Figure D.4. B)  E-cadherin negative controls of MCF-7cell line in confocal microscopy. Where 
the primary antibody was excluded it was marked ―no primary‖ and when a secondary antibody 
was excluded it was marked ―no secondary‖. The top panel shows the controls for the DAPT 
treated cells and the bottom panel shows controls for DBZ treated cells. 
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Figure D.5. A) E-cadherin negative controls of MDA-MB-231cell line in confocal microscopy. 
Where the primary antibody was excluded it was marked ―no primary‖ and when a secondary 
antibody was excluded it was marked ―no secondary‖. The top panel shows the controls for the 
untreated cells and the bottom panel shows controls for DMSO vehicle control. 
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Figure D.5.B) E-cadherin negative controls of MDA-MB-231cell line in confocal microscopy. 
Where the primary antibody was excluded it was marked ―no primary‖ and when a secondary 
antibody was excluded it was marked ―no secondary‖. The top panel shows the controls for the 
DAPT treated cells and the bottom panel shows controls for DBZ treated cells. 
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Figure D.6.A) E-cadherin negative controls of MDA-MB-436 cell line in confocal microscopy. 
Where the primary antibody was excluded it was marked ―no primary‖ and when a secondary 
antibody was excluded it was marked ―no secondary‖. The top panel shows the controls for the 
untreated cells and the bottom panel shows controls for DMSO vehicle control. 
B) 
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Figure D.6 B) E-cadherin negative controls of MDA-MB-436 cell line in confocal microscopy. 
Where the primary antibody was excluded it was marked ―no primary‖ and when a secondary 
antibody was excluded it was marked ―no secondary‖. The top panel shows the controls for the 
DAPT treated cells and the bottom panel shows controls for DBZ treated cells. 
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D.3 MCF-7 cell line E-cadherin expression 
 
Figure D.7. The E-cadherin expression and localisation in MCF-7 cell line. E-cadherin (red) 
appears to be expressed in the cytoplasm, the cell membrane as well as the nucleus (blue). 
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Appendix E: Scratch/Migration assay analysis 
E.1 Calculations of cell migration 
The distance between two borders of the cells created by the scratch, was measured at 3 
points on the image (Figure E.1 orange arrows), using the Imagej software.  The distance 
was calculated in pixels.  The distance in pixel/µm was given by the formula Distance in 
pixels\known distance X 1.0 pixel aspect ratio which is performed by ImageJ 
automatically. The averages of the 3 were calculated as the average distance for one 
scratch. As each experiment included 3 biological repeats (Figure E.2-4) every gap on each 
image was measured using this method.  The average distance for each triplicate was 
regarded as the average distance in pixels/µm. 
 
 
Figure E.1.Scratch image analyses. An example of the three points (orange arrows) at which the 
gap was measured using Imagej Software. 
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Figure E.2 Scratch image analyses. An example of DAPT treated cells in triplicates at 0 hours, 2 
hours and 4 hours. The white arrows indicate gap closure 
 
Figure E.3. Scratch image analyses. An example of DAPT treated cells in triplicates at 24 hours, 
26 hours and 28 hours. The white arrows indicate gap closure 
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Figure E.4 Scratch image analyses.  An example of DAPT treated cells in triplicates at 48 hours. 
The white arrows indicate gap closure. 
 
 
 
E.2 Raw data for gap closure plots 
Table E.1: The average distances of MCF-7 cell line pixel/µm calculated on ImageJ. 
 
  average   
Time 
(hours) 
UNTREATED DMSO DAPT DBZ 
                   
0 
5.405 6.111333333 4.665667 6.683 
2 4.557333333 4.604 6.32 4.918667 
4 5.899 5.397 5.668 4.196667 
24 3.301333333 4.269 4.112333 5.429667 
26 3.193333333 3.918666667 3.385667 3.609 
28 3.271 3.883 3.539667 2.476 
48 1.886333333 2.302333333 2.483667 2.769333 
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Table E.2: The standard deviations of MCF-7 cell line pixel/µm calculated on ImageJ. 
 
  SDV   
Time 
(hours) 
UNTREATED DMSO DAPT DBZ 
0 0.54086875 0.175845 0.85770411 0.077788 
2 0.13875278 0.366283 0.32261897 0.453244 
4 0.56357165 0.534506 0.91279571 0.299067 
24 0.58704032 0.543617 0.57189626 0.314607 
26 0.74377707 0.605004 0.68207429 0.313651 
28 1.14852993 1.423559 0.42602856 0.116052 
48 0.52401559 0.432551 0.57452618 0.368138 
 
 
Table E.3: The average distances of MDA-MB-231 cell line pixel/µm calculated on 
ImageJ. 
  average   
Time 
(hours) 
UNTREATED DMSO DAPT DBZ 
 4.252 3.555 6.020667 5.709667 
2 4.24 4.36533333 4.330667 3.832667 
4 4.62133333 4.727 4.397667 4.100667 
24 4.09333333 3.80366667 2.513333 3.895333 
26 3.287 3.096 3.723 3.241333 
28 2.619 3.03833333 4.225667 3.224333 
48 1.277 2.614 2.594667 0.930333 
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Table E.4: The standard deviation MDA-MB-231cell line pixel/µm calculated on ImageJ. 
 
  SDV   
Time 
(hours) 
UNTREATED DMSO DAPT DBZ 
0 0.245036732 0.495254 0.588145 0.15232 
2 0.50610572 0.190264 0.350423 0.441799 
4 0.595760299 0.527787 0.190327 0.83001 
24 0.525178382 0.628673 0.707094 0.369197 
26 0.424625718 0.659737 0.838485 0.443741 
28 0.847488643 0.694784 0.473407 0.393983 
48 0.459568276 0.522943 0.876286 0.366757 
 
Table E.5: The averages distances of MDA-MB-436 cell line pixel/µm calculated on 
ImageJ. 
  averages   
Time 
(hours) 
UNTREATED DMSO DAPT DBZ 
0 6.432 6.223 6.228667 6.089667 
2 5.999333333 5.61366667 5.597333 4.828667 
4 5.483333333 5.10233333 5.917 5.108333 
24 4.118666667 3.927 4.115 4.960667 
26 4.235666667 4.08466667 3.587667 4.909333 
28 4.615 3.62166667 4.274333 5.071333 
48 3.899333333 4.501 3.672 4.468667 
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Table E.6: The standard deviations of MDA-MB-436 cell line pixel/µm calculated on 
ImageJ. 
  SDV   
Time 
(hours) 
UNTREATED DMSO DAPT DBZ 
0 0.488430138 0.138156 0.182506 0.45581 
2 0.246579264 0.105406 0.40721 0.183664 
4 0.334156151 0.205432 0.117478 0.368419 
24 0.311872303 0.330002 0.792121 0.434403 
26 0.148708888 0.105078 0.639207 0.426809 
28 0.476087177 0.162312 0.492526 0.366571 
48 0.173727756 0.681954 0.822658 0.577243 
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APPENDIX F: Statistical analyses and turn-it-in report 
All statistical data was calculated with Graphpad Prism 5 Software version 5 below are all 
the outputs from the analysis. 
 
 
 Table F.1: Results from the Kruskal-Wallis test of the effect of DBZ on MCF-7, MDA-
MB-231 and MDA-MB-436 cell lines. 
 
Table Analysed Effect of DBZ on MCF-7,MDA-
MB-231 and MDA-MB-436 
    
Kruskal-Wallis test   
P value P<0.0001 
Exact or approximate P value? Gaussian Approximation 
P value summary *** 
Do the medians vary signif. (P < 0.05) Yes 
Number of groups 3 
Kruskal-Wallis statistic 206.4 
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Table F.2: Results from the Kruskal-Wallis test of the effect of DAPT on MCF-7,MDA-
MB-231 and MDA-MB436 cell lines. 
 
Table Analysed Effect of DAPT on MCF-
7,MDA-MB-231 and MDA-
MB-436 
    
Kruskal-Wallis test   
P value P<0.0001 
Exact or approximate P value? Gaussian Approximation 
P value summary *** 
Do the medians vary signif. (P < 0.05) Yes 
Number of groups 3 
Kruskal-Wallis statistic 201.0 
 
 
Table F.3: Results from the Kruskal-Wallis test of the normal growth curves of MCF-7, 
MDA-MB-231, and MDA-MB-436 cell lines. 
 
Table Analysed Growth curve 
    
Kruskal-Wallis test   
P value P<0.0001 
Exact or approximate P value? Gaussian Approximation 
P value summary *** 
Do the medians vary signif. (P < 0.05) Yes 
Number of groups 3 
Kruskal-Wallis statistic 174.8 
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Table F.4: Results from the unpaired student’s t-test between the growth curves of MCF-7 
and MDA-MB-231 cell lines. 
 
Table Analysed Growth curve MCF-7 VS 
MDA-231 
Column A MCF-7 
vs vs 
Column B MDA-MB-231 
    
Unpaired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=16.05 df=294 
    
How big is the difference?   
Mean ± SEM of column A 6.265 ± 0.1685 N=148 
Mean ± SEM of column B 3.177 ± 0.09299 N=148 
Difference between means 3.088 ± 0.1924 
95% confidence interval 2.711 to 3.465 
R squared 0.4669 
    
F test to compare variances   
F,DFn, Dfd 3.282, 147, 147 
P value P<0.0001 
P value summary *** 
Are variances significantly different? Yes 
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Table F.5: Results from the unpaired student’s t-test between the growth curves of MCF-7 
and MDA-MB-436.   
 
Table Analysed Growth curve MCF-7 vs MDA-
MB-436 
Column A MCF-7 
vs vs 
Column B MDA-MB-436 
    
Unpaired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=17.70 df=294 
    
How big is the difference?   
Mean ± SEM of column A 6.265 ± 0.1685 N=148 
Mean ± SEM of column B 3.165 ± 0.04780 N=148 
Difference between means 3.099 ± 0.1751 
95% confidence interval 2.756 to 3.442 
R squared 0.5159 
    
F test to compare variances   
F,DFn, Dfd 12.42, 147, 147 
P value P<0.0001 
P value summary *** 
Are variances significantly different? Yes 
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Table F.6: Results from the unpaired student’s t-test between the effects of DAPT on the 
cell proliferation and viability of the MCF-7 and MDA-MB-231 cell lines.  
 
Table Analysed DAPT comparison between MCF-7 and MDA-
MB-231 
Column A MCF-7 
vs vs 
Column B MDA-MB-231 
    
Unpaired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=28.90 df=193 
    
How big is the difference?   
Mean ± SEM of column A 2.240 ± 0.06337 N=98 
Mean ± SEM of column B 0.3982 ± 0.001644 N=97 
Difference between means 1.841 ± 0.06372 
95% confidence interval 1.717 to 1.966 
R squared 0.8123 
    
F test to compare variances   
F,DFn, Dfd 1501, 97, 96 
P value P<0.0001 
P value summary *** 
Are variances significantly different? Yes 
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Table F.7: Results from the unpaired student’s t-test between the effects of DAPT on the 
cell proliferation and viability of the MCF-7 and MDA-MB-436 cell lines. 
 
Table Analysed DAPT comparison between MCF-7 and MDA-MB-
436 
Column A MCF-7 
vs vs 
Column B MDA-MB-436 
    
Unpaired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=28.74 df=192 
    
How big is the difference?   
Mean ± SEM of column A 2.240 ± 0.06337 N=98 
Mean ± SEM of column B 0.3452 ± 0.01582 N=96 
Difference between means 1.894 ± 0.06591 
95% confidence interval 1.765 to 2.024 
R squared 0.8114 
    
F test to compare variances   
F,DFn, Dfd 16.37, 97, 95 
P value P<0.0001 
P value summary *** 
Are variances significantly different? Yes 
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Table F.8: Results from the unpaired student’s t-test between the effects of DBZ on the 
cell proliferation and viability of the MCF-7 and MDA-MB-231 cell lines. 
 
Table Analysed DBZ comparison between MCF-7 and MDA-MB-
231 
Column A MCF-7 
vs vs 
Column B MDA-MB-231 
    
Unpaired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=16.93 df=193 
    
How big is the difference?   
Mean ± SEM of column A 1.421 ± 0.06245 N=98 
Mean ± SEM of column B 0.3579 ± 0.002118 N=97 
Difference between means 1.064 ± 0.06281 
95% confidence interval 0.9404 to 1.187 
R squared 0.5977 
    
F test to compare variances   
F,DFn, Dfd 878.3, 97, 96 
P value P<0.0001 
P value summary *** 
Are variances significantly different? Yes 
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Table F.9: Results from the unpaired student’s t-test between the effects of DBZ on the 
cell proliferation and viability of the MCF-7 and MDA-MB-436 cell lines. 
 
Table Analysed DBZ comparison between MCF-7 and MDA-MB-
436 
Column A MCF-7 
vs vs 
Column B MDA-MB-436 
    
Unpaired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=17.55 df=192 
    
How big is the difference?   
Mean ± SEM of column A 1.421 ± 0.06245 N=98 
Mean ± SEM of column B 0.3024 ± 0.009160 N=96 
Difference between means 1.119 ± 0.06375 
95% confidence interval 0.9941 to 1.244 
R squared 0.6161 
    
F test to compare variances   
F,DFn, Dfd 47.45, 97, 95 
P value P<0.0001 
P value summary *** 
Are variances significantly different? Yes 
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Table F.10: Results from the paired student’s t-test between the effects of DAPT vs DBZ 
on the cell proliferation and viability of the MCF-7 cell line. 
 
Table Analysed MCF-7 DAPT VS 
DBZ 
Column A DAPT 
vs vs 
Column B DBZ 
    
Paired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=94.01 df=97 
Number of pairs 98 
    
How big is the difference?   
Mean of differences 0.8182 
95% confidence interval 0.8009 to 0.8355 
R squared 0.9891 
    
How effective was the pairing?   
Correlation coefficient (r) 0.9905 
P Value (one tailed) P<0.0001 
P value summary *** 
Was the pairing significantly effective? Yes 
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Table F.11: Results from the paired student’s t-test between the effects of DAPT vs DBZ 
on the cell proliferation and viability of the MDA-MB-231 cell line. 
 
Table Analysed MDA-MB-231 DAPT vs DBZ 
Column A DAPT 
vs vs 
Column B DBZ 
    
Paired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=23.98 df=96 
Number of pairs 97 
    
How big is the difference?   
Mean of differences 0.04034 
95% confidence interval 0.03700 to 0.04369 
R squared 0.8569 
    
How effective was the pairing?   
Correlation coefficient (r) 0.6257 
P Value (one tailed) P<0.0001 
P value summary *** 
Was the pairing significantly effective? Yes 
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Table F.12: Results from the paired student’s t-test between the effects of DAPT vs DBZ 
on the cell proliferation and viability of the MDA-MB-436 cell line. 
 
Table Analysed MDA-MB-436 DAPT vs DBZ 
Column A DAPT 
vs vs 
Column B DBZ 
    
Paired t test   
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=6.363 df=95 
Number of pairs 96 
    
How big is the difference?   
Mean of differences 0.04285 
95% confidence interval 0.02946 to 0.05624 
R squared 0.2989 
    
How effective was the pairing?   
Correlation coefficient (r) 0.9968 
P Value (one tailed) P<0.0001 
P value summary *** 
Was the pairing significantly effective? Yes 
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Table F.13: Results from the Kruskal-Wallis test on the cell migration of MCF-7 cell 
lines. 
 
Table Analysed MCF-7 migration assay anova 
    
Kruskal-Wallis test   
P value 0.3916 
Exact or approximate P value? Gaussian Approximation 
P value summary ns 
Do the medians vary signif. (P < 0.05) No 
Number of groups 4 
Kruskal-Wallis statistic 3.000 
 
 
Table F.14: Results from the Kruskal-Wallis t-test on the cell proliferation and viability of 
the MDA-MB-231 cell line. 
 
Table Analysed MDA-MB-231 migration assay 
ANOVA 
    
Kruskal-Wallis test   
P value 0.3916 
Exact or approximate P value? Gaussian Approximation 
P value summary ns 
Do the medians vary signif. (P < 0.05) No 
Number of groups 4 
Kruskal-Wallis statistic 3.000 
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Table F.15: Results from the Kruskal-Wallis t-test on the cell migration of the MDA-MB-
436 cell line. 
 
Table Analysed MDA-MB-436 MIGRATION 
ASSAY ANOVA 
    
Kruskal-Wallis test   
P value 0.3916 
Exact or approximate P value? Gaussian Approximation 
P value summary ns 
Do the medians vary signif. (P < 0.05) No 
Number of groups 4 
Kruskal-Wallis statistic 3.000 
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Table F.16: Results from the paired student’s t-test between the effects of DAPT vs DBZ 
on the cell migration of the MCF-7 cell line. 
 
Table Analysed Migration assay MCF-7 DAPT VS 
DBZ 
Column A DAPT 
vs vs 
Column B DBZ 
    
Paired t test   
P value 0.9804 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.02564 df=6 
Number of pairs 7 
    
How big is the difference?   
Mean of differences 0.01324 
95% confidence interval -1.250 to 1.277 
R squared 0.0001096 
    
How effective was the pairing?   
Correlation coefficient (r) 0.5431 
P Value (one tailed) 0.1039 
P value summary ns 
Was the pairing significantly effective? No 
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Table F.17: Results from the paired student’s t-test between the effects of DAPT vs DBZ 
on the cell proliferation and viability of the MDA-MB-436 cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table Analysed MDA-MB-436 
migration assay 
Column A DAPT 
vs vs 
Column B DBZ 
    
Paired t test   
P value 0.4015 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.9026 df=6 
Number of pairs 7 
    
How big is the difference?   
Mean of differences -0.2921 
95% confidence interval -1.084 to 0.4998 
R squared 0.1195 
    
How effective was the pairing?   
Correlation coefficient (r) 0.6763 
P Value (one tailed) 0.0476 
P value summary * 
Was the pairing significantly effective? Yes 
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Table F.18: Results from the paired student’s t-test between the effects of DAPT vs DBZ 
on the cell proliferation and viability of the MDA-MB-231 cell line. 
 
Table Analysed MDA-MB-231 migration 
assay 
Column A DAPT 
vs vs 
Column B DBZ 
    
Paired t test   
P value 0.2867 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.169 df=6 
Number of pairs 7 
    
How big is the difference?   
Mean of differences 0.4102 
95% confidence interval -0.4483 to 1.269 
R squared 0.1856 
    
How effective was the pairing?   
Correlation coefficient (r) 0.7637 
P Value (one tailed) 0.0228 
P value summary * 
Was the pairing significantly effective? Yes 
 
 
 
 
 
